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 Hippocrates ,the father of Medicine (460 B.C.-375 B.C) coined the term 
“Karkinos” for the non healing neoplastic ulcers and “Karkinoma’’ for the solid 
malignant tumours.  Both the terms derived from Greek. “Karkinos” means 
“Crab’’. The reason behind the terminology is the malignant tumors adhere to 
any part ,which it seizes upon in an obstinate manner like crab.18 
 The term “Oral cancer’’ is used to describe any malignancy that arises 
from the oral tissues. Oral cancer is the most life threatening disease of oral 
tissues, causing a major health problem in India. 18 
 Oral cancer is the sixth most common cancer worldwide and continues 
to be the most prevalent cancer related to the consumption of tobacco, arecanut, 
alcohol and other carcinogenic products.  Increasing awareness on part of the 
providing treatment, as well as the population in general, has led to a large 
proportion of patients presenting with earlier stage of the disease.31   
 Several studies have shown clearly that oral cancers either develop from 
precancer or are associated with it.  The problem of oral precancer and cancer in 
India has been investigated extensively and its incidence has been shown to be 
really high. 
 Epidemiological studies indicate that intervention at an early stage 
might reduce oral carcinoma related morbidity and mortality.  This includes 
detection of oral cancer at its precancerous stage. The discovery of 
immunological markers at blood level, histological and molecular level has 
revolutionized the diagnosis and prognosis in oral precancerous and cancer 
lesions.15 
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 Oral cancer is generally preceded by some precancerous lesions and 
conditions for a varying length of time.  They share the same etiological factors 
with oral cancer, particularly the use of tobacco and areca nut exhibit the same 
site and habit relationship. 
 Precancerous lesion is a morphologically altered tissue in which cancer 
is more likely to occur than its apparently normal counterpart. Leukoplakia and 
Erythroplakia are precancerous lesions.  Precancerous condition is defined as 
generalized state associated with a significantly increased risk for cancer. Oral 
submucous fibrosis and Erosive lichen planus are precancerous conditions .12         
 Individuals with oral precancer such as oral leukoplakia and oral 
submucous fibrosis run a risk that is 69 times higher for them to develop oral 
cancer compared to tobacco users who do not have pre cancer. The recognition 
and management  of precancerous lesions and conditions  therefore constitutes a 
vital oral cancer control measure.49 
 In India, oral cancer is prevalent in most areas where tobacco related 
practices are observed. For development of oral cancer, tobacco is the single 
greatest risk factor.  This is due to higher concentration of carcinogenic 
exposure and failure to clean the carcinogens from the mucosal surface. 
 Alcohol, areca nut, viruses, sunray, smoking, genetic mutations, 
Syphilis,chronic irritation and diet deficiency states are also implicated in the 
etiology. The development of oral cancer is a multistep process arising from 
pre-existing potentially malignant lesions. Leukoplakia is the most common 
precancer representing 85% of such lesions.   
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 Likewise, the incidence of Oral Submucous Fibrosis (OSMF) is 
increasing like an epidemic, targeting the younger generation. The etiology for 
OSMF is still obscure and a varied number of factors have been proposed. Of 
these, areca nut use is the most important and persistent finding in history 
taking.1,49 
 Immune complexes are clusters of interlocking antigens and antibodies. 
Under normal conditions immune complexes are rapidly removed from the 
bloodstream by macrophages in the spleen and Kupffer cells in the liver. In 
some circumstances, however, immune complexes continue to circulate.6 
 Immune complexes may themselves cause disease when they are 
deposited in organs,such as in certain forms of vasculitis. This is the third form 
of hypersensitivity in the Gell-Coombs classification, called Type III 
hypersensitivity.33 
 Immune complex deposition is a prominent feature of several 
autoimmune diseases, including systemic lupus erythematosus, 
cryoglobulinemia, rheumatoid arthritis, scleroderma and Sjögren's syndrome. 
 Circulating immune complex disease occurs when the host's antibody 
production, relative to the amount of antigens, is inadequate for prompt 
elimination of antigen. Normally, excess amounts of antibody are formed which 
generate large immune complexes that are removed very rapidly from the 
circulation and are disposed of by the mononuclear phagocytic system. If the 
antibody response is very poor, only a few very small complexes are formed 
and are  prone for vascular deposition.33  
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 When the relative antibody production is such that complexes of 
intermediate size form, vascular trapping can occur and injury results from the 
effects of inflammation. In addition to immune complex size, other factors 
influence vessel deposition, including the efficiency of systemic clearance of 
immune complexes, the hemodynamics of blood flow, and vasoactive amine-
influenced changes in vascular permeability.33 
 Intensive studies have documented the role of immune complexes as 
modulators of both cellular and humoral immune response. The occurrence of 
Circulating Immune Complexes (CIC) as a marker for tumor burden and 
prognosis in the sera of patients with oral precancer and cancer is now well 
established.64,65  
 Recent advances in the fields of Circulating Immune Complexes, tumor 
progression, drug resistance, tumor cell heterogeneity and metastasis have 
resulted in a renewed interest in the development of non- specific 
immunotherapeutic modalities . 
           The overall consensus is that only a small percentage of the detected CIC 
in vivo represent tumor associated antigens complexed with antibodies. The 
bulk of CIC most likely represent auto antibodies or the reaction to denatured 
self proteins, microbes, normal lymphocyte, antigens and nuclear antigens. 
Antigenic make up of CIC in cancer patients reflects the host's immune 
response to a variety of often overlapping antigenic stimuli and hence paves 
way for further studies.43 
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 Immunological and biochemical alterations in the sera of such patients 
can help not only in early diagnosis, appropriate treatment but also as indicators 
of prognosis, as the disease progresses.  CIC represent the host's physiological 
and immunological defense response in eliciting specific antibodies upon 
exposure to most antigenic substances..54 
 This study was conducted to understand the role  of these CICs in the 
oral potentially malignant disorders like oral leukoplakia and OSMF. It can be 
suggested that immunological assessment  of markers such as  CIC in  oral 
precancer  patients may help in earlier diagnosis and prognosis of these 
lesions/conditions. Since ,CIC levels in Serum  helps in predicting malignant 
potential of the pre malignant lesions/conditions it can be used as a reliable 
biomarkers. 
O 
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Aim: 
 
 To validate Circulating immune complexes as biological marker for 
Oral Leukoplakia and Oral submucous fibrosis. 
 
 
Objectives: 
1. To determine the levels of Circulating immune complexes  in 
subjects with untreated Oral Leukoplakia and untreated Oral 
submucous fibrosis. 
 
2. To compare the  Circulating immune complexes in Oral Leukoplakia 
and Oral submucous fibrosis levels with the control group. 
 
3. To detect the relation between circulating immune complexes with 
oral leukoplakia and Oral submucous fibrosis. 
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The study is about the Estimation of Circulating immune complexes 
in Oral leukoplakia and Oral sub mucous fibrosis patients in comparison 
with healthy normal controls.  To obtain a meaningful study and result, a 
proper and detailed review of the literature is of utmost importance.  The 
present literature review is about the various aspects of Oral leukoplakia, 
Oral sub mucous fibrosis, and their correlation with Circulating immune 
complexes levels. 
 
PRECANCEROUS LESIONS AND CONDITIONS: 
Precancerous lesion: 
Precancerous lesion is a morphologically altered tissue in which 
cancer is more likely to occur than its apparently normal counterpart. 
It includes: Leukoplakia, Erythroplakia and palatal lesions in reverse 
smokers.101 
Precancerous condition: 
Precancerous condition is generalized state associated with 
significantly increased risk of cancer. 
It includes: Oral sub mucous fibrosis, Actinic keratosis, Lichen 
planus and Discoid lupus erythematosis, Syphilis and Siderophenic 
dysphagia. 
A new terminology has been recommended as “Potentially 
malignant disorders” which included not only the lesions and conditions but 
also includes a family of morphological alterations among which few may 
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have an increased potential for malignant transformation.  These potentially 
malignant disorders have been further classified as lesions and conditions.  
But currently they recommend not dividing them as such, but instead 
clubbing them together under the heading of “Potentially malignant 
Disorders”. 100,101 
ORAL LEUKOPLAKIA: 
Historical review: 
Erno Schwimmer in 1877 37, a Hungarian dermatologist was the 
first person to describe Oral Leukoplakia. He originally proposed the term 
“Leukoplakia” which literally means “White patch”.  In Greek “Leukos” 
means white and “Plakia” means patch. It describes a clinical entity. 
Sprage in 1963 37 found that 36% of American oral pathologists 
used Oral leukoplakia as clinical term and 40% as histological one.  
Shafer in 1967 37 suggested that histological definition of 
leukoplakia is however complicated by the fact that not all lesion satisfying 
the histological criteria for leukoplakia will appear clinically as a white 
patch. 
W.H.O Collaborating Centre for Oral Precancerous Lesions in 
1978 37 proposed that the term Leukoplakia should be used to describe a 
clinical entity, that is a white patch of oral mucosa which is not removed by 
rubbing and not classifiable as any other oral disease like oral lichen planus, 
leukedema, candidiasis ,white sponge nevus, lupus erythematosus .  It also 
  
Review of Literature   
 
 
9 
 
suggests that microscopically leukoplakic lesions should be described in 
internationally approved term. 
 Brad W. Neville et al in 2002 9 proposed that as such 
leukoplakia should be used only as a clinical term and it has no specific 
histopathological connation should  never be used as microscopic diagnosis.  
Sometimes a white patch is initially believed to represent leukoplakia, but 
the biopsy reveals another specific diagnosis.  In such cases, the lesion 
should no longer be categorized as leukoplakia.   
Definition of leukoplakia: 
WHO collaborating centre for oral precancerous lesions in   
1978 37 defined oral leukoplakia as “A white patch or plaque that cannot be 
characterized clinically or pathologically as any other disease.” 
Axell T et al in 1996 2 defined leukoplakia as “A white patch or 
plaque that cannot be characterized clinically or pathologically as any other 
disease and is not associated with any physical or chemical causative agent 
except the use of tobacco”. 
Axell T et al in 1996 2 also defined oral leukoplakia as “A 
predominantly white lesion of oral mucosa that cannot be characterized as 
any other definable lesion; some leukoplakia will transform in to cancer.” 
Pindborg et al in 1997 58 defined leukoplakia as “A predominantly 
white lesion of the oral mucosa that cannot be characterized as any other 
definable lesion”. 
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WHO in 2005 101 declared “Leukoplakia should be used to 
recognize white patch of questionable risk having excluded other known 
diseases or disorders that carry no increased risk for cancer” 
Epidemiology: 
In a 10 year prospective study in India in large samples, carried out 
in several geographic areas with various kinds of tobacco usage, the annual 
age- adjusted incidence rates of leukoplakia per 1000 population per year  
varied from 1.1 -2.4 among men and from 0.2 -1.3 among women and  the 
prevalence varied from 0.2-4.9%. 29 
The annual incidence was 2.1 per 1000 men 1.3 peer 1000 women 
and the  highest being in people with mixed habits, that 6 per 1000.99 
Prevalence of leukoplakia in India varies from 0.2-5.2%. Prevalence 
of 0.59 also has been reported. 80 
Prevalence of leukoplakia was reported to be 3.6% and that of 
preleukoplakia was 6.4%.  Idiopathic leukoplakia was reported to be 0.7% 
and tobacco specific leukoplakia was 2.9%. 2  
In Ernakulam district the prevalence of leukoplakia was 17 per 1000 
population.  It was more commonly seen in people with mixed habit.   
            Less than 15 of men below the age of 30 years, have leukoplakia, but 
the prevalence increases to an alarming 8% in men over the age of 70 years. 
The prevalence in women past the age 70 years is approximately 2%.8   
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Age:  
The onset of lesions usually starts after 30 years, resulting in peak 
incidence of 50 years.  Leukoplakia is seen most frequently in middle aged 
and older men, with an increasing prevalence with age.  Oral leukoplakia 
can occur 5 years prior to oral cancer.36 
Gender: 
It has a strong male preponderance.  Leukoplakia is a commonly 
occurring lesion particularly in patients after 40 years of age.    The male to 
female ratio is 2:1.  The gender distribution in most studies varies, ranging 
from a strong male predominance in different parts of India, to almost 1:1 in 
Western world.96 
Etiology: 
Many causative agents have been implicated in the etiology of 
leukoplakia.  They include Tobacco, Alcohol, Chronic friction due to sharp 
tooth, Electro galvanic reaction, Ultra violet radiation, Syphilis. 36.  
Tobacco use is considered to be the primary cause for the occurrence 
of leukoplakia.  Leukoplakia associated with smoking habit seems to have 
less malignant potential than those not related to smoking habit.  In a study 
of 257 patients with oral leukoplakia, 183 were smokers, out of whom 12% 
developed carcinomas, whereas 74 were non- smokers out of whom 32% 
developed carcinoma. 86 
Local factors like chronic irritation and malocclusion which 
constantly irritate the oral mucosa cause oral leukoplakia.  Irritation by ill 
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fitting dentures, overhanging crowns and fillings and poor restoration refers 
to traumatic causes.  Smoking is also considered as an irritant due to drying 
effect on the mucosa.  These exciting factors should act on a susceptible 
host. Heredity plays an important role in determining an individual’s 
susceptibility or resistance to the development of leukoplakia. 85 
            Systemic factors include hormonal alterations and nutritional 
deficiencies.  Estrogen deficiency may determine the susceptibility of 
females to develop leukoplakia at the period of menopause.   
            Vitamin A deficiency may produce Hyperkeratosis in experimental 
animal. Continuous irritants such as spicy food may also be a factor.  
Irritating mouthwashes can also be a cause but the exact role is yet to be 
substantiated.   
            Syphilis may also be responsible for leukoplakic lesions on tongue 
secondary to atrophic glossitis of tertiary syphilis.  The glossitis is 
apparently more highly susceptible to the action of local irritants in the 
mouth. 36 
               In one preliminary study Epstein Barr virus was detected in 60% of 
Proliferative verrucous leukoplakia cases suggesting its possibility as an 
etiological agent. 
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              Yeast organism especially candida albicans can cause leukoplakia 
since it has the ability to form N-Nitrosomethylamines from the precursors 
which are abundantly available in the saliva of smokers.  
To list them under a table as 36: 
Local Systemic 
Local irritation 
 Sharp ,malposed teeth 
 Ill fitting denture 
 Poor restorations 
 
Heredity 
Occlusal disharmony Harmonal factors 
Occlusal habit Estrogen deficiency 
Thermal factors Nutritional deficiency 
Smoking Syphilis 
Irritant foods,chemicals,mouthwashes, etc. Atrophic glossitis 
Clinical types 7, 100 : 
Two main types exist: 
 Homogeneous 
 Non homogeneous 
Distinction between these two forms is purely clinical, based on surface 
color and morphological characteristics like thickness which also has 
predilection for prognosis. 
Homogeneous type: 
Homogeneous leukoplakia has been defined as a predominantly 
white lesion of uniform flat, thin appearance that may exhibit shallow cracks 
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and has a smooth, wrinkled or corrugated surface with a constant texture 
throughout.  The risk of malignant transformation is relatively low. The 
lesion is predominantly white but can be grayish white.  It constitutes for 
about 84% of the leukoplakia. 
Non homogeneous type: 
 Ulcerative: Mixed white and red in color but retaining the 
predominant white character. 
 Nodular (Speckled): Small polypoid outgrowths, rounded red 
or white excrescences. 
 Verrucous: wrinkled or corrugated surface appearance. 
The term “Erythro leukoplakia” is applied for predominantly red and 
white lesion that may be irregularly flat, nodular or exophytic.  The nodular 
lesions are characterized by white patches or nodules on a erythematous 
base. 
Ulcerative leukoplakia: 
Ulcerative leukoplakia is characterized by areas of red which at 
times exhibit yellowish areas of fibrin.  White patches are generally present 
at the periphery.  It constitutes to about 135 of all leukoplakia types. It could 
also present with ulceration with white areas in between.  Some times they 
occur with minimal keratinisation. 
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Speckled leukoplakia: 
Speckled leukoplakia is also called Nodular leukoplakia.  It is 
characterized by small white specks or nodules on an erythematous base.  
The term nodular leukoplakia was proposed by Pindborg et al in 1968 57 
based on the findings at the labial commisure.  The nodules are very fine, 
speckled, pin head sized or even larger.  It constitutes to about 3% of 
leukoplakia.  It is important lesion because of its high risk for  malignant 
transformation 
Verrucous leukoplakia; 
Verrucous leukoplakia appears as an exophytic lesion with irregular 
sharp or blunt projections.   
Clinical features: 
Oral leukoplakia accounts for 80% of all leukoplakia of upper aero 
digestive tract. Most of the others are vocal cord lesions and are called as 
laryngeal keratosis.  It can occur any where in the oral cavity.  The site of 
leukoplakia depends on the type of smoking habit, the quality and the 
quantity of the tobacco. 
Most commonly involved sites are retro commissural area, buccal 
mucosa, edentulous alveolar ridge, hard palate, tongue, lips.  The gingival, 
soft palate and floor of mouth are less commonly involved in an Indian 
population, where as it is not true for Western population.  
Leukoplakia begins as thin, gray white plaques that may appear 
somewhat translucent, sometimes fissured or wrinkled and are soft and flat.  
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They usually have sharply demarcated borders but occasionally blend 
gradually in to normal mucosa.  This early stage is considered as Phase –I 
Leukoplakia.   
Thin leukoplakia may continue unchanged or disappear, but with 
time 2/3rd of these lesions acquire a distinct white appearance from a 
thickened keratin layer. It becomes leathery to palpation and fissures 
deepen.  There may be few or localized nodules or appear as surface 
projections.  This can be categorized as Phase-II.  
 Most of these lesions remain unchanged and about 2/3rd regress and 
disappear and few become severe.  Later these lesions develop surface 
irregularities of a nodular or granular leukoplakia.  Numerous pointed 
projections develop on the surface and give an appearance of verruciform 
leukoplakia.  Both these lesions are Phase-III lesions with similar progress.  
Phase-III lesions may become dysplastic or invasive with no change in 
clinical appearance.   
Over time an additional surface change occurs and multiple circular 
or oval patches of non blanching redness appear in scattered areas.  Such 
areas represent site at which cells are so immature that they are unable to 
produce keratin.  These forms Phase-IV lesions.    
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Leukoplakia Clinical phases 36: 
Phase Descriptive terms Risk of malignant 
transformation 
 
I 
Thin leukoplakia 
Preleukoplakia 
Homogeneous 
leukoplakia 
 
+/- 
 
II 
Thick,smooth 
leukoplakia 
Fissured leukoplakia 
Homogeneous leukoplkia 
 
++ 
 
 
 
III 
Granular leukoplakia 
Verruciform leukoplakia 
Rough leukoplakia 
Candidal epithelial 
hyperplasia 
Homogeneous 
leukoplakia 
 
 
+++ 
 
 
IV 
Erythroleukoplakia 
Speckled leukoplakia 
Candidal leukoplakia 
Nonhomogeneous 
leukoplakia 
 
++++ 
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Pindborg et al in 1997 58 has given the classification and staging for 
leukoplakia as follows, 
Classification and staging of oral leukoplakia   
Provisional (Clinical Diagnosis) 
L: Extent of leukoplakia 
          L0: No evidence of lesion 
          L1: ≤ 2 cm 
          L2: 2-4 cm 
          L3: ≥ 4cm 
S: Site of leukoplakia 
          S1: all sites excluding floor of mouth & tongue 
          S2: floor of mouth &/ tongue 
          S3: not specified 
C: Clinical aspect 
           C1: homogeneous 
           C2: non homogeneous 
           C3: not specified 
Definitive diagnosis :( Histopathological diagnosis) 
P: Histopathological features 
             P1: no dysplasia 
             P2: Mild dysplasia 
             P3: Moderate dysplasia 
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             P4: severe dysplasia 
             Px: not specified 
Staging: 
1. any L,S1,C1,P1 or P2 
2. any L,S1or S2,C2,P1 or P2 
3. any L,S2,C2,P1 or P2   
4. any L,any S,any C,P3 or P4. 
 
Natural history: 
Leukoplakia can regress spontaneously without any intervention in 
habit or by any other means in about 40% of cases.  Significantly higher 
rates of regression is seen who discontinue the tobacco habit.  In one long 
term follow-up study among the Swedish population consisting 104 
samples, they found that oral leukoplakia has disappeared in 43% of the 
people.  About 70-80% of leukoplakia is associated with tobacco habits; 
also about 80% of the leukoplakia lesions disappear completely about 58% 
or regress within 12 months after smoking cessation. 11 
Malignant transformation: 
It is generally accepted that dysplastic lesions carry a 5 fold greater 
risk than non dysplastic ones. It refers to the development of oral cancer 
from preexisting oral leukoplakia. So  it is necessary to follow-up a case of 
leukoplakia for a period of 3 months to one year. 12  
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            In the period of follow-up, the lesion should be evaluated for 
development of thickened/nodular areas, ulcerations, rolled margins, 
growths or indurated areas.  Since these changes represent early oral 
cancers.  Lesions on the tongue, lip vermilion border, floor of the mouth 
accounts for 93% of the leukoplakia with dysplastic changes or carcinoma. 
Globally 3-6% leukoplakia change to cancer.27, 28, 84 
Non homogeneous leukoplakia accounted for the highest frequency 
of malignant transformation of 20%, whereas 3% of the homogeneous 
leukoplakia developed carcinoma.  Proliferative verrucous leukoplakia has a 
malignant transformation rate as high as 70.3% with mean follow-up of 
11.6% 12, 25, 51 
Differential diagnosis 44, 55:  
The following differential diagnosis should be kept in mind whenever a 
clinical diagnosis of leukoplakia is made:  
 Surface debris. This can be scrapped off with a tongue blade or 
gauze.  
 Acute pseudo membranous candidiasis (Thrush). White, curd-like or 
cotton like patches or plaques, most frequently occurring on the 
buccal mucosa and tongue, but also seen on the palate, floor of 
mouth and gingiva. They are usually associated with a burning 
sensation and the white plaque can usually be wiped away with 
gauze, leaving a tender, red area beneath, which may bleed. 
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 Reactive hyperkeratosis. A benign epithelial response, usually due to 
trauma from a fractured tooth or dental restoration. Check for the 
causative agent.  
 Leukedema :Usually bilateral, that disappears on stretching the 
mucosa. 
 Lichen planus : Usually bilateral with lacy white pattern. 
 Lichenoid reaction: same like lichen planus;but positive history of 
drug intake, amalgam restoration, pan chewing habit. 
 Linea Alba buccalis : Usually bilateral. The white line is present 
along the occlusal plane.   
Diagnosis : 
Axell in 1996 2 suggested that diagnosis of leukoplakia can be 
arrived at by excluding lesions belonging to other entities, such as Lichen 
planus,Lupus erythematosus, Leukedema and White sponge nevus and 
lesions for which an etiology can be established ,such as frictional keratosis, 
cheek/lip/tongue biting, contact lesions and smokers palate. 
           Pindborg in 1997 58 proposed that when there is a doubt in 
diagnosing leukoplakia ,one can make a provisional diagnosis of 
leukoplakia and the definitive diagnosis can be established after the result of 
removal of any possible etiologic factors and a biopsy.  
Review on oral leukoplakia: 
Racugno V, Cossu F in 1969 63 , reviewed influence of tobacco 
smoke on the origin of leukoplakia and carcinomas of the mouth, with 
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special reference to smokers of cigars with the lighted end in the mouth and 
found there is significant relation between tobacco smoke and leukoplakia.  
Sugár.L. et al in 1969 90, made a follow-up study with 324 patients 
and concluded that there was a relationship between smoking and the 
frequency of leukoplakia. He also found that alcohol, mechanical irritants 
and electric potential difference in the mouth were also important etiological 
factors, particularly in combination. Many of the cases with mild symptoms 
improved when the etiological agent was removed. 
            Waldron C A and  Shafer W G. in 1975 99 made a clinico 
pathologic study with 3256 oral leukoplakia cases .  During a 13-year 
period, 3256 specimens clinically diagnosed as leukoplakia (('keratosis," 
"white patch") were analyzed as to age of occurrence, site of involvement. 
            It was found that: leukoplakia occurs chiefly in the 5th, 6th, and 7th 
decades; about half of the lesions involved the mandibular mucosa, 
mandibular sulcus, and buccal mucosa; leukoplakia was slightly more 
common in men (54.2%). 
            Bánóczy J in 1977 5 made a follow-up study  with 670  patients with 
oral leukoplakia during a 30-year-period showed cancer development in 40 
cases, The age distribution revealed the prevalence of leukoplakia in the 
age-group 51-60 years; that of carcinoma in the age-group of 61-70 years. 
The sex distribution showed a male-female ratio of 3.2: 1 in the leukoplakia-
group, and a 1.9: 1 ratio in the carcinoma-group. The tongue and the lips 
were the site of predilection for malignant transformation and for dysplasia. 
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Among etiological factors, Candida albicans infection and the simultaneous 
existence of several etiological factors seemed to play a role in malignant 
transformation. Erosive leukoplakia showed the highest risk, developing in 
25.9% of the cases into cancer. 
Sciubba JJ. in 2001 81 reviewed the importance of early diagnosis 
and treatment of oral cancer and suggested that there is strong evidence for 
an etiological relationship between human papilloma virus and a subset of 
head and neck cancers. It is generally accepted that most sporadic tumors 
are the result of a multi-step process of accumulated genetic alterations. 
These alterations affect epithelial cell behavior by way of loss of 
chromosomal heterozygosity which in turn leads to a series of events 
progressing to the ultimate stage of invasive squamous cell carcinoma.  
The corresponding genetic alterations are reflected in clinical and 
microscopic pathology from hyperplasia through invasiveness. A wide 
range of mucosal alterations are closely related to leukoplakia. Proliferative 
verrucous leukoplakia represents a relatively new type of leukoplakia that is 
separate from the more common or less innocuous form of this condition. 
Erythroplakia is particularly relevant considering its almost certain 
relationship with dysplasia or invasive carcinoma. 
Squamous cell carcinoma will develop from antecedent dysplastic 
oral mucosal lesions if an early diagnosis has not been made and treatment 
given. Early diagnosis within stages I and II correspond to a vastly 
improved 5-year survival rate when compared with more advanced stage III 
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and IV lesions. Surgical management of this disease remains the mainstay of 
treatment. Other therapies include radiation and chemotherapy options that 
may be used adjunctively and palliatively. Following treatment, it is 
important to understand the significant risks of second primary cancers 
developing within the upper aero digestive tract as a result of field 
cancerization. The most important message is that early detection of the 
asymptomatic early stage oral cancer translates in general terms to 
satisfactory clinical outcome and cure in most patients.  
Dietrich T in 2004 19 made an analytical study on Clinical risk 
factors of oral  leukoplakia and found the results as, Tobacco smoking as the 
strongest independent risk factor. The Odds Ratio were 3.00 (0.77-11.8) for 
< for =10 cigarettes/day and up to 6.01 (2.4-15.0) for >20 cigarettes/day. 
Diabetes, age and socio-economic status were found as independent 
predictors of Oral leukoplakia. Alcohol consumption, race/ethnicity, years 
of education and Body Mass Index showed no independent association with  
Oral leukoplakia Females  with a history of estrogen use were less likely to 
have Oral leukoplakia with an Odds ratio  of 0.34 (0.11-1.07).  
Chung CH  et al in 2005 12 made a study to find the relation 
between Oral precancerous disorders  with areca quid chewing, smoking, 
and alcohol drinking in southern Taiwan and found of 1075 subjects,136  
12.7%).  Precancerous lesions and conditions were detected .The analysis of 
the spectrum of oral precancerous disorders detected, leukoplakia (n = 80), 
OSMF (n = 17) and verrucous lesions (n = 9), demonstrated an association 
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with gender (P < 0.001). There were statistically significant associations 
among leukoplakia (P < 0.01), OSMF (P < 0.0001), and verrucous lesions 
The synergistic effect of smoking and areca quid chewing habit on 
leukoplakia and OSMF was demonstrated. Conclusion of this study 
reinforced the association of current areca quid chewing without tobacco, 
cigarette smoking, and alcohol drinking to leukoplakia, Oral submucous 
fibrosis, and verrucous lesions in Taiwan. 
 Lee JJ et al in 2006 40 conducted a study to find the relation 
between carcinoma and oral leukoplakia and demonstrated the results that 
some leukoplakias contain a malignant component. Lesions with certain 
features are more prone to carcinoma, but no clinical attributes can bring 
certainty in these lesions. 
Prakash C.Guptha in 2006 60 made an Epidemiologic study of the 
association between alcohol habits and oral leukoplakia. The study included 
10914 individuals for their tobacco and alcohol habits and examined for the 
presence of oral leukoplakia. Very few females (1.6%) were found to be 
alcohol users and they were excluded from further analysis. Among 7604 
males, 30.4% used alcohol regularly, 25.4% occasionally and 44.2% were 
non-users. The prevalence of leukoplakia was significantly higher among 
regular (5.7%) and occasional (3.9%) users than among non-users (2.9%) of 
alcohol.  
Alcohol usage was found to be related to age as well as tobacco 
habits. The prevalence of leukoplakia was higher among alcohol users in 
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each age-group as well as in each tobacco habit category. After age-
adjustment the difference between alcohol users and non-users, although 
reduced, remained significant. For most tobacco habit categories the trend 
remained similar after age-adjustment except for the mixed habits group, for 
which there was a reversal of the trend. The alcohol habit may, perhaps, 
produce discernible effects only in association with other 'weak' etiological 
risk factors, such as a single tobacco habit of smoking or chewing rather 
than a 'strong' etiologic factor such as the mixed habits of chewing and 
smoking.  
Sol Silverman in 2006 86 made a follow up study on oral 
leukoplakia and Malignant transformation in 257 patients for average period 
of 7.2 years .Seventy-three percent of the patients used tobacco, with 
cigarette usage being the predominant form. Forty-five patients (17.5%) 
subsequently developed squamous carcinomas . High risks for malignant 
transformation also included non-smoking patients, the clinical presence of 
erythroplasia (erythroleukoplakia), and a clinical verrucous-papillary 
hyperkeratotic pattern. Duration of the leukoplakia progressively increased 
the total number of malignant transformations, with the largest rate 
occurring in the second year. This study confirms that oral leukoplakia is a 
precancerous lesion and that certain characteristics indicate greater risks and 
warrant consideration of more aggressive management.  
Thomas SJ et al in 2008 94 conducted a cross sectional study on 
Betel quid not containing tobacco and oral leukoplakia .The study recruited 
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1,670 adults. They recorded betel quid chewing and smoking. The 
prevalence of leukoplakia was 11.7%. In the nested case-control study of 
197 cases and 1,282 controls, current betel chewing was associated with 
increased risk of leukoplakia with an adjusted odds ratio for current chewers 
of 3.8 (95% CI 1.7, 8.4) and in the heaviest chewers of 4.1 (95% CI 1.8, 9.1) 
compared to non-chewers. Current smoking was associated with an 
increased risk of leukoplakia with an adjusted odds ratio for current smokers 
of 6.4 (95% CI 4.1, 9.9) and amongst heaviest smokers of 9.8 (95% CI 5.9, 
16.4) compared to non-smokers. The systematic review identified 5 studies 
examining risk of leukoplakia associated with betel quid chewing in 
populations where betel quid did not contain tobacco and that controlled for 
smoking. In studies that adjusted for smoking, the combined random effect 
odds ratio was 7.9 (95% CI 4.3, 14.6) in betel quid chewers. The results of 
this study and systematic review of similar studies provide evidence of the 
role of betel quid not containing tobacco and leukoplakia                     
Van der Waal I  in 2009 97 reviewed Potentially malignant disorders 
of the oral and oropharyngeal mucosa; terminology, classification and 
present concepts of management and gave WHO workshop 
recommendations such  as to abandon the distinction between potentially 
malignant lesions and potentially malignant conditions and to use the term 
potentially malignant disorders instead. Of these disorders, leukoplakia and 
erythroplakia are the most common ones. These diagnoses are still defined 
by exclusion of other known white or red lesions. In spite of tremendous 
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progress in the field of molecular biology there is yet no single marker that 
reliably enables to predict malignant transformation in an individual patient. 
The general advice is to excise or laser excision of any oral oropharyngeal 
leukoplakia/erythroplakia, if feasible, irrespective of the presence or absence 
of dysplasia. Nevertheless, it is actually unknown whether such removal 
truly prevents the possible development of a squamous cell carcinoma  
 
ORAL SUBMUCOUS FIBROSIS : 
Historical review :  
Oral submucous fibrosis has been well established in Indian medical 
literature since the time of Sushrutha renowned Indian Physician who lived 
in the era 2500-3000 B.C.56 
           Schwartz J in 1952, 56 first described Oral submucous fibrosis in 
modern literature among five East African women of Indian Origin under 
the term “ Atropica idiopathica mucosa oris”.  Since then this condition has 
been described by various investigators by various terms. 
           Joshi S G in 1953,56 described this condition in India when he 
reported 41 cases with Oral submucous fibrosis of the palate and it was he 
who suggested the use of the term “Oral submucous fibrosis’’.  
Lal.D in 1953 56 described it as a “Diffuse Oral submucous 
fibrosis”,Joshi S.G in 1953 described it as “Sub mucous fibrosis of the 
palate and pillars”,Sui-Pin in 1954 described it as “Idiopathic scleroderma 
of the mouth”,Rao.A.B.N in 1962 termed it ias “Idiopathic palatal 
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fibrosis”,Behl P.N in 1962 arrtibuted the term “Sclerosing stomatitis’’. 
Definition: 
The most widely accepted definition is by Pindborg J.J and           
Sirsat SM in 1966 56. They have defined Oral submucous fibrosis as “An 
insiduous chronic disease affecting any part of oral cavity and sometimes 
the pharynx, although occasionally preceded by vesicle formation it is 
always associated with juxta –epithelial inflammatory reaction followed by 
a fibro elastic change of the lamina propria,with epithelial atrophy leading to 
stiffness of the oral mucosa and causing trismus and inability to eat.” 
Schwartz in 195256, coined the term atrophica idiopathica mucosa 
oris to describe an oral fibrosing disease .He discovered in 5 Indian women 
from Kenya. 
 Joshi in 1953 56 subsequently coined the term Oral sub mucous 
fibrosis (OSMF) for the condition. 
Epidemiology: 
           Oral submucous fibrosis is an epidemic in India, and is prevalent 
throughout Indian sub continent, sparing no caste or creed, affecting the 
young and old, the rich and poor alike.10 
           Pindborg J.J et al in 1966 56 reported that the prevalence of Oral 
submucous fibrosis in India ranges from 0.2-0.5%wiht a higher 
predominance in the southern part of the Indian subcontinent. 
Pindborg J.J in 1968 57 conducted an epidemiological survey 
comparing the incidence of Oral sub mucous fibrosis in Urbanized Indians 
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with those of rural Indians and observed that the incidence varied from 0%  
in Bihar to 0.4% in Kerala in rural Indians and 0.18% in Bangalore to 1.22% 
in Trivandrum in urbanized Indians. They concluded that Oral sub mucous 
fibrosis is more prevalent in South India than in North India. 
Reports from Western India gives an incidence of 2.6 and 8.5 per 
1,00,000 per year for males and females respectively.  In South India it is 9 
and 20 per 1,00,000 per year for males and females respectively. 
            He stated that South Indian state of Kerala, one new case could be 
expected per 10,000 populations per year.   The prevalence rate of oral 
submucous fibrosis in South Africa, Burma and India range from 0-1.2%. 
Gupta P.C et al in 1989 29 ,reported the incidence of Oral 
submucous fibrosis in Ernakulum ,India as 8 per 10,000 per men and 19 per 
10,000 women per year.  In India Bhavnagar, in Western India the incidence 
was 2.6 per 10,000 men and 8.15 per 10,000 women per year. 
About 2.5 million people are affected by this disease.  There is clear 
cut geographical predisposition to South East Asia. Most of these cases are 
found in India although cases have been reported in Taiwan, Malaysia, 
South Africa, New Guniea,Sri lanka,Burma,United kingdom and Canada.93       
Age : 
           There is no predilection for any age group however a broad age 
distribution with a peak in the range of 20-40 years was observed. 32   
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Gender : 
There is equal sex distribution, though some reports may vary 
indicating a female preponderance.26 
Etiology : 
           The prime causes suspected on the basis of cause and effect 
relationship are prolonged and chronic use of arecanut, chillies, tobacco 
with arecanut, Pan masala,Pan ,Vitamin B complex deficiency. 
           Arecanut chewing has the strongest evidence regarding the etiology.  
Arecanut is the endosperm of the fruit areca catechu tree, the fruit of which 
is orange yellow in colour when ripe 71.   
           A 10 year prospective study on 10,000 subjects showed a zero 
incidence of oral submucous fibrosis among those who did not chew 
arecanut compared with an incidence of 35 per 10,000 among arecanut 
chewers.10 
           It has been shown that arecanut and its extract mainly arecoline can 
stimulate fibroblast proliferation, collagen synthesis and increasing collagen 
cross linking in  in invitro studies.  The flavinoids and tannins from betel nut 
can stabilize collagen and render them resistant to degradation by 
collagenase.66 
           Among systemic factors the main ones incriminated are chronic Iron, 
Vitamin B complex deficiency and anemia.  Iron metabolism is important in 
maintaining the health of oral mucosa as well as the epithelium of the 
digestive tract and it contributes to normal enzyme activity.26    
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Clinical features : 
            The major presenting complaint is progressive inability to open the 
mouth owing to the accumulation of inelastic fibrous tissue in the 
juxtaepithelial region of the oral mucosa.  Patients may describe a sudden 
onset of inflammation or ulceration of the oral mucosa and burning pain 
while eating highly seasoned food that previously caused no distress.68 
           The fibrosis also leads to difficulty in mastication speech and 
swallowing, pain in the throat and ears and relative loss of auditory acuity 
due to stenosis of the Eustachian tube. 68 
           In the early cases the fibrosis is seen arching from the anterior pillars 
in to the soft palate as a delicate reticulum of interlacing white strands 
which later become confluent.  In the cheeks a mottled marble like 
appearance may be seen when dense pale depigmented fibrosed areas 
alternate with pinker normal mucosa.50, 67 
           The floor of the mouth become pale and thickened, the tongue gets 
reduced in size and mobility; bands of encircling collagen distort lips.   
           At any stage in the disease the overlying epithelium may become the 
site of nonspecific ulceration, dysplastic change or malignant 
transformation.  If fibrosis extends in to the esophagus the patient may 
experience progressive dysphagia and reduced esophageal mobility.48, 49 
           Patients with Oral sub mucous fibrosis often complains of sudden 
onset of inflammation or ulceration of oral mucosa with vesicle formation 
and increased sensitivity or burning sensation when eating spicy food that 
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are followed by trismus,increasing difficulty in mastication speech and 
swallowing.64,65 
           In advanced cases the jaws may be in separable and the total inelastic 
mucosa is forced against the buccal aspects of the teeth were sharp edges or 
restorations may cause ulcerations which become secondarily infected.  The 
fibrosis progress in to the posterior part of the buccal mucosa, the anterior 
pillar of fauces and the soft palate including uvula.  48, 49,62                                       
Gupta P C and Dinesh Chandra in 1992 30 suggested the Clinical 
Grading  as follows, 
The diagnosis of Oral submucous fibrosis is based on the positive 
history of areca nut chewing, Clinical and histopathological criteria.  The 
severity of the disease can be graded based on the clinical grading system. 
Grade I : 
           Presence of only blanching of oral mucosa with out symptoms, 
Grade II : 
           Presence of blanching and burning sensation, dryness mouth, vesicles 
or ulcers in the mouth. 
Grade III : 
           Presence of blanching and burning sensation, dryness mouth, vesicles 
or ulcers in the mouth with restriction of mouth opening and palpable bands 
all over the mouth with out tongue involvement.       
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Grade IV :  
           Presence of blanching and burning sensation, dryness mouth, vesicles 
or ulcers in the mouth with restriction of mouth opening and palpable bands 
all over the mouth without tongue involvement.       
Grade V : 
           Presence of all features of Grade IV with tongue involvement. 
Grade VI : 
           Oral sub mucous fibrosis along with histopathologically proven 
carcinoma.            
 
Malignant transformation:                   
           Paymaster in 1956 56 was the first one to mention the precancerous 
nature of Oral submucous fibrosis when he observed the development of 
slowly growing Squamous cell carcinoma in One third of his Oral 
submucous fibrosis patients. There is 3-19% malignant transformation in 
Oral sub mucous fibrosis.    
           Pindborg J.J in 1966 56 reported that Oral submucous fibrosis 
patients in India have higher occurrence of leukoplakia and carcinomas than 
those without this disease. 
 
Murthi P.R et al in 1995 48 conducted a follow-up study of 66 
patients over a 17-year period, and found cancer developed in 7.6% of 
patients. 
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Pindborg J.J in 1997 58 summarised the criteria in support of the 
precancerous nature of the disease as, 
1. Higher prevalence of leukoplakia among Oral submucous fibrosis 
patients. 
2. High frequency of epithelial dysplasia. 
3. Concurrent finding of Oral submucous fibrosis in oral cancer 
patients. 
4. Histological diagnosis of carcinoma without clinical suspicion of it 
and 
5. Incidence of oralcancer patients with oral submucous fibrosis. 
Differential diagnosis 44 : 
1. Radiation induced fibrosis : which is confirmed by proper history 
taking regarding cancer history and radiation therapy.  
2. Scleroderma: which is detected by the clinical features of the disease 
like progressive sclerosis all over the body, including skin and 
internal organs. 
3. Fibrosis due to Actinomycosis infection  : Patients history reveals 
period of infection  and the treatment obtained. 
4. Fibrosis due to Trauma : patient history reveals history of trauma, 
surgery. 
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Review on Oral Submucous Fibrosis: 
           Maher R et al in 1994 42 conducted a case control study in Role of 
arecanut in the causation of Oral submucous fibrosis. Information on habits 
was collected by personal interview of 157 cases and 157 controls. Despite 
overall female preponderance, a substantial number of young men were 
enlisted. The male/female risks were found to be similar.  
No differences between risks were found when comparing the three 
age categories, 0-20, 21-40, 41-60 yr. Among the cases, an increased risk 
was observed for areca nut chewing. This habit when practiced alone 
appeared to have the highest risk (Relative Risk 154), followed by pan with 
or without tobacco (Relative Risk 64, 32 respectively). Logistic regression 
and discriminant analysis showed that daily consumption rates appeared to 
be more important with respect to risk than lifetime duration of habit.  
           Tobacco habits were more prevalent amongst those 15 cases who 
presented with concurrent carcinoma and OSMF. They concluded that areca 
nut chewing has a causal relationship with OSMF. Additional tobacco insult 
may be necessary for subsequent carcinoma development. 
           Rajendran.R in 1994 64 reviewed the etiology and pathogenesis of 
Oral submucous fibrosis.  According to him oral sub mucous fibrosis, a pre 
cancerous condition of the oral cavity has been studied by a number of 
workers in the field.  The available epidemiological data showed a clear cut 
geographical and ethnic pre dispositions, which suggested that certain 
customs or habits (chewing) prevalent among the population groups in 
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South East Asia might be possible etiological factors.  However none of 
these customs was shown to be casually linked.  This led some workers to 
consider the importance of systemic pre dispositions, in addition to the 
effects of local factors on the oral mucosa.  More research is needed to 
elucidate this problem.  
Shah N and Sharma R  in 1994 82 conducted Immunological 
studies in oral submucous fibrosis. He evaluated in 113 cases and 25 
controls. The male/female ratio was 1.5/1. The mean age of males was 
significantly lower than that of females. The mean ESR levels were within 
normal limits, but for a higher than 20 mm fall per hr. in 40% of the cases. 
The serum IgA, IgG, and IgM levels were elevated significantly as 
compared to the controls. Circulating auto-antibodies and tissue-deposited 
antibodies were also found in 33% and 40% of the cases, respectively. From 
the analysis of the results, it is difficult to ascribe an auto-immune basis for 
the causation of OSMF. The female bias and elder age group, the factors 
generally considered in favour of an immune disorder, was not found in the 
study. However, raised ESR in 40% and serum globulin levels in 47% of the 
patients, distinctly higher levels of serum immunoglobulins, and positivity 
for circulating and tissue deposited antibodies in 33% and 34% of the cases 
respectively, do indicate an immunological basis. 
Murti.P.R. in 1995 48 reviewed the etiology of oral submucous 
fibrosis, a high risk pre cancerous condition, predominantly affecting 
Indians.  Consumption of chilly was hypothesized as an etiologic factor on 
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the basis of ecological observations and a solitary animal experimental 
study.  Subsequent epidemiologic studies that included case-series reports, 
large cross-sectional surveys, case control studies, cohort and intervention 
studies have identified arecanut as the major etiologic factor.  Currently the 
role of genetic susceptibility and that of autoimmunity are receiving 
attention.  Influence of nutritional factors if any remains unclear.                     
         Gupta PC, et al in 1998 32 conducted a study in India A total of 
11,262 men and 10,590 women aged 15 years and older were interviewed 
for their tobacco habits. Among 5018 men who reported the use of tobacco 
or areca nut, 164 were diagnosed as suffering from OSF. All but four cases 
were diagnosed among 1786 current areca nut users (age-adjusted relative 
risk: 60.6). Areca nut was used mostly in mawa, a mixture of tobacco, lime 
and areca nut, and 10.9% of mawa users had OSF (age-adjusted relative 
risk: 75.6). The disease as well as areca nut use was concentrated (about 
85%) in the lower (< 35 years) age group. They concluded the study by 
depicting an increase in the prevalence of OSF, especially in the lower age 
groups, directly attributable to the use of areca nut products. This could lead 
to an increase in the incidence of oral cancer in the future.  
         Shah N, Sharma PP in 1998 83 conducted a study to identify the role 
of chewing and smoking habit in the etiology of oral submucous fibrosis. In 
this study 236 cases of oral submucous fibrosis were compared with 221 
control subjects matched for age, sex and socioeconomic conditions. It was 
found that chewing of areca nut, quid and pan masala was directly related to 
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oral submucous fibrosis and not a single case was found without any 
chewing habit.  
The study showed that the pan masala chewers develop oral 
submucous fibrosis in half the time taken by areca nut betel quid chewers. It 
was also found that duration of chewing was not significantly correlated but 
the frequency of chewing was directly correlated to manifestation of oral 
submucous fibrosis. 
Zain RB et al in 1999 102 reviewed Oral mucosal lesions association  
with betel quid, areca nut and tobacco chewing habits. A variety of 
betel/areca nut/tobacco habits have been reviewed and categorized because 
of their possible causal association with oral cancer and various oral 
precancerous lesions and conditions, and on account of their widespread 
occurrence in different parts of the world.  He found that there is strong 
association between betel quid, arecanut, tobacco chewing habits and 
lesions such as chewer's mucosa, areca nut chewer's lesion, oral submucous 
fibrosis and other quid-related lesions.  
Rajendran.R in 2003 68, reviewed the etiology, clinical features, 
epidemiology, pathology and management of Oral submucous fibrosis and 
concluded in his study as Oral submucous fibrosis is a chronic progressive, 
scaring disease that predominantly affects people of South East Asian 
origin.   
Ranganathan K et al in 2004 69 conducted a case control study in 
south India, over a 3 year period. A total of 185 consecutive patients with 
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OSF were matched with age- and sex-matched controls. History was 
recorded in a pre-determined format by qualified Dental Surgeons. The 
results obtained were , the male to female ratio of OSF cases was 9.9 : 1. All 
areca nut products were associated with OSF, with the risk being greatest 
for pan masala. The duration of the habit was more significant than the 
frequency of the chewing habit. The present study confirms the strong 
association between areca nut use and OSF and the increasing use of pan 
masala.  
           Punnya V et al in 2010, 61 made a a clinicopathologic  study of 205 
cases in Indians. The study evaluated 205 cases of oral submucous fibrosis 
for the age, sex, site of involvement, duration of disease at the time of 
diagnosis, associated habits and common presenting symptoms, presence of 
other mucosal lesions, malignant potential, and the histopathology.  
The results  revealed  Oral submucous fibrosis seen in younger age 
(20–30 years) than that reported in literature and showed a characteristic 
male preponderance. A strong association with smokeless tobacco use 
especially arecanut in the form of gutkha was established and was related to 
earlier development of oral sub mucous fibrosis  within a year of the habit. 
A total of 11.6% of cases were associated with malignancy and occurred 
predominantly in males.  
CIRCULATING IMMUNE COMPLEXES: 
            Immune complexes are clusters of interlocking antigens and 
antibodies. Under normal conditions immune complexes are rapidly 
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removed from the bloodstream by macrophages in the spleen and Kupffer 
cells in the liver. In some circumstances, however, immune complexes 
continue to circulate. 
           Immune complexes may themselves cause disease when they are 
deposited in organs, e.g. in certain forms of vasculitis. This is the third form 
of hypersensitivity in the Gell-Coombs classification, called Type III 
hypersensitivity. 
           Immune complex deposition is a prominent feature of several 
autoimmune diseases, including systemic lupus erythematosus, 
cryoglobulinemia, rheumatoid arthritis, scleroderma and Sjögren's 
syndrome. 52, 72, 87 
           Circulating immune complex disease occurs when the host's antibody 
production, relative to the amount of antigens, is inadequate for prompt 
elimination of antigen. Normally, excess amounts of antibody are formed 
which generate large immune complexes that are removed very rapidly from 
the circulation and are disposed of by the mononuclear phagocytic system. 
If the antibody response is very poor, only a few very small complexes are 
formed which are not prone to vascular deposition. 14 
           When the relative antibody production is such that complexes of 
intermediate size form, vascular trapping can occur and injury results from 
the effects of inflammation. In addition to immune complex size, other 
factors influence vessel deposition, including the efficiency of systemic 
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clearance of immune complexes, the hemodynamics of blood flow, and 
vasoactive amine-influenced changes in vascular permeability.78 
           Intensive studies have documented the role of immune complexes as 
modulators of both cellular and humoral immune response. The occurrence 
of Circulating Immune Complexes as a marker for tumor burden and 
prognosis in the sera of patients with oral precancer and cancer is now well 
established. Recent advances in the fields of CIC, tumor progression, drug 
resistance, tumor cell heterogeneity and metastasis have resulted in a 
renewed interest in the development of non- specific immunotherapeutic 
modalities .23,24 
The overall consensus is that only a small percentage of the detected 
CIC in vivo represent tumor associated antigens complexed with antibodies. 
The bulk of CIC most likely represent auto antibodies or the reaction to 
denatured self proteins, microbes, normal lymphocyte, antigens and nuclear 
antigens. Antigenic make up of CIC in cancer patients reflects the host's 
immune response to a variety of often overlapping antigenic stimuli and 
hence paves way for further studies.82 
Immunological and biochemical alterations in the sera of such 
patients can help not only in early diagnosis, appropriate treatment but also 
as indicators of prognosis, as the disease progresses.  CIC represent the 
host's physiological and immunological defense response in eliciting 
specific antibodies upon exposure to most antigenic substances. CIC 
deposition further leads to inflammation and tissue/ cell damage. It also 
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leads to suppression of cell mediated immunity and modulates the humoral 
responses.78 
           Circulating immune complexes are normally removed by the 
mononuclear phagocytic cells. However, circulating immune complexes 
formations or their defective clearance under certain circumstances becomes 
detrimental to the host, resulting in pathological deposition. Thus, altering 
the host immunological response leading to inflammation and tissue injury .  
It can be suggested that immunological and biochemical assessment  
of markers such as  CIC in  oral precancer  patients may help in earlier 
diagnosis and/or prognosis of these lesions. The CIC levels in Serum also 
help in predicting malignant potential of the pre malignant lesions.38, 72,78, 95. 
Review on Circulating Immune Complexes:  
            Digeon et al in 1977 20 investigated for elevated  circulating immune 
complexes by precipitation tests using Poly Ethylene Glycol (PEG) on a 
series of normal and pathological sera. Various factors affecting PEG 
precipitation were studied. Immunoglobulins and complement factors 
precipitated by PEG (3.5%) were quantified and their significance was 
discussed in relation to serum levels. The PEG test was compared to labeled 
Complement 1q binding test with a fairly good correlation.  
The direct evaluation of the amount of Complement 4 precipitated 
with IgG by 3% PEG provided a simpler routine assay than the C1q binding 
test for detecting complement-fixing immune complexes. The direct PEG 
test and the C4 test gave positive results in patients with diseases generally 
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presumed to be associated with immune complexes including Systemic 
lupus erythematosus, Acute glomerulonephritis, Sub-acute bacterial 
endocarditis and Chronic active hepatitis. The demonstration of Hepatitis B 
surface antigen and antibody after acid dissociation of PEG precipitates 
from Hepatitis B seronegative sera illustrated the fact that PEG does 
precipitate and thus concentrates circulating immune complexes. 
           Ríha et al in 1979 74  used poly ethylene glycol for immune 
complex detection in human sera. Proteins precipitated from diluted sera of 
patients suffering from diseases with Circulating Immune Complexes by 
3.75% Polyethyleneglycol (PEG) were studied. The low solubility at 
neutral pH and the good solubility at pH 8.4 with the finding of 
immunoglobulins and complement components in these precipitates and the 
presence of aggregates larger than 19S found by ultracentrifugation in 
positive sera are further proofs that under these conditions preferably IC are 
precipitated.' 
These results revealed the conclusion that the 3.75% PEG 
precipitation of human sera diluted 1:30 in borate buffer, pH 8.4, is a 
reliable method for IC detection, especially useful for screening of large 
number of sera and for isolation of IC from positive sera.  
           Crispian Scully in 1983 13 summarised in his study the evidence for 
the involvement of the immune response in the development of neoplasia, 
and discussed the immunological abnormalities found in patients with head 
and neck carcinoma, and outlined the recent attempts at treatment of patients 
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with head and neck carcinoma by modulation of the immune response 
which is also known as Immunotherapy. 
           Krapf F et al in 1983 39 ,studied the elevated levels of circulating 
immune complexes in malignant diseases.  By using three different assay 
methods, circulating immune complexes have been detected in 85% of sera 
from patients with malignant melanoma, and in 77% of sera from patients 
with breast cancer. These methods were a C1q-binding assay, a double-
antibody conglutinin-binding ELISA, and a polyethylene glycol 6000 
precipitation technique followed by quantitative determination of 
immunoglobulins in the redissolved precipitate.  
           Detection rates of circulating immune complexes using any one of 
these methods separately ranged from 33% to 56%, indicating the presence 
of different types of circulating immune complexes in cancer patients' sera. 
The combined use of the three methods mentioned resulted in an increased 
diagnostic sensitivity and a doubling of the predictive value 95. However, 
tests for circulating immune complexes cannot be considered as useful 
parameters for early diagnosis of cancer, since the comparatively low 
incidence of malignancies in the population at large, together with the 
presence of circulating immune complexes in other, nonmalignant, diseases 
of considerable prevalence, appears to preclude effective application of any 
nonspecific method for early diagnosis of cancer in general.      
           Ostreiko K.K. et al in 1983 53, used a method for rapid 
determination of average masses and concentrations of circulating immune 
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complexes in human sera is suggested. It is based on the dissimilarity in 
solubilities of immune complexes with different masses in the presence of 
polyethyleneglycol. Light-scattering intensities are measured by a laser 
nephelometer after adding to the serum of PEG in two different 
concentrations. The experimental values of the average masses and 
concentrations are calculated using calibration curves. The calibration 
curves are plotted for model immune complexes with different average 
masses obtained by heat-aggregation of IgG at various concentrations. This 
technique has been employed for determination of the average masses and 
concentrations of circulating immune complexes in 17 patients suffering 
from systemic lupus erythematosus and in 8 control individuals.they 
concluded theren exists significsnt correlation  between curve values and 
CIC level in sera. 
Daniel P. Eskinazi in 1984 16 reviewed Advantages of sequential 
polyethylene glycol (PEG) precipitations to isolate and analyze circulating 
immune complexes.  He reported a new approach utilizing sequential 
polyethylene glycol 6000 (PEG) precipitations to isolate and analyze 
circulating immune complexes (CIC). Two experimental systems were 
studied. He concluded that PEG concentrations needed to precipitate CIC 
cannot be predetermined, as they are a function of the size and probably the 
nature of the CIC studied. This limitation can be overcome by the 
systematic sequential precipitations which increase the chances of 
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identifying antigens and decrease the risks of confusing antigen-antibody 
complexes and Ig aggregates. 
Endo L et al in 1985 22 reviewed Clinical utility of assays for 
circulating immune complex. There are now many assays for the 
quantification of circulating immune complexes, each with distinct 
specificity and sensitivity. In a wide variety of rheumatic, infectious, 
neoplastic, and metabolic conditions, levels of circulating immune 
complexes may be elevated.  
           In selected situations, determination of circulating immune complex 
levels may help clinicians in the management of their patients. In lupus 
erythematosus, circulating immune complex levels, in conjunction with 
other immune parameters, may provide more insight into the disease course 
and activity than assessment of end organ parameters alone. In the 
differential diagnosis of infective endocarditis, serial levels of circulating 
immune complexes may provide evidence of effectiveness or failure of 
treatment. There is evidence that assays for circulating immune complexes 
may be of potential benefit in the management of Lyme disease and acute 
myelogenous leukemia. 
           Prabha Balaram et al  in 1987 59 made a study on Immunology of 
premalignant and malignant conditions of the oral cavity .Quantitation of 
circulating immune complexes (CIC) levels was established in patients with 
oral cancer and oral precancerous lesions. The levels were compared with 
that in normal controls and chronic chewers of betal quid with no signs of 
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any disease. Both patients with oral cancer and oral precancerous lesions 
had elevated CIC when compared to both the control groups. The most 
interesting observations were (a) the CIC levels in the chewing controls 
were significantly raised when compared to normal controls; and (b) the 
CIC levels in the patients with premalignant lesions were elevated almost to 
the same levels as in the oral cancer patients. 
          Mehar Aziz et al in 1992 46 , made a study to detect CIC Child 
malignancy. Circulating immune complexes (CIC) were estimated in 28 
cases of Non-Hodgkin's lymphomas, Hodgkin's disease, bone and soft tissue 
sarcomas in the pediatric age group by polyethylene glycol (PEG) 
precipitation and latex agglutination inhibition (LAI) techniques. 
           Results were comparted with 25 age matched controls. Highly 
significant CIC values were obtained by LAI technique (P<0.01) as 
compared to PEG precipitation technique (P<0.05) in malignancy. However, 
seropositivity for CIC in lymphomas and Hodgkin's disease was 85.71 per 
cent by LAI test as compared to 57.14 per cent by PEG pptn test. In sarcoma 
group, seropositivity for CIC was 57.11 per cent by LAI test and 28.57 per 
cent by PEG precipitation test. 
           Combination of both these tests increases the sensitivity of immune 
complex detection in serum of cancer patients. CIC begin to rise in serum in 
early stages of neoplastic transformation, and the level of CIC is directly 
proportional to proliferating tumor mass in vivo. 
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Vijay kumar et al  in 1993 98 reviewed  Immunological phenomena 
in human oral carcinoma in India and concluded that there exists significant 
correlation between immunological alterations and degree of lesion from 
precancer to cancer.  He emphasized that many oral cancers first present as a 
precancerous lesion and hence it is important to understand the biological 
factors associated with such lesions. The immune system and its functioning 
is a significant element in the development of cancer. Considerable evidence 
exists suggesting that the immune response plays a role in regulating the 
development and growth of oral precancers.  He reviewed various 
immunological abnormalities associated with oral precancers including cell 
surface changes, alterations in cell mediated immune reactions and humoral 
immune abnormalities. 
Makoto Kawata  et al in 1998 43 in his study detected Epithelial 
Ovarian-Cancer-Associated Antigens Involved in Immune Complexes by 
Monoclonal Antibodies.  To detect antigenic molecules involved in immune 
complexes (ICs) in patients with epithelial ovarian cancer, they developed 
several monoclonal antibodies (Mabs) by hybridoma technology from mice 
immunized with ovarian cancer tissues. Hybridoma supernatants were 
differentially screened with a panel of ICs purified from ascitis of patients 
with ovarian cancer and with ICs from pooled normal human sera by the 
Enzyme-Linked Immuno Sorbent Assay (ELISA).                     
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           Furthermore, ICs detected, were elevated in the sera from 18 of 42 
(42.9%) patients with epithelial ovarian cancer, but not in those from 39 
patients with benign ovarian tumors or from 29 healthy individuals. 
Sunali S Khanna et al in 2006 91evlauated the role of Circulating 
Immune Complexes and trace elements (Copper, Iron and Selenium) as 
markers in oral precancer and cancer in a randomised, controlled clinical 
trial. In serum of patients with Oral submucous fibrosis, oral leukoplakia, 
and Oral squamous cell carcinoma (OSCC), Circulating immune complexes 
(CIC) were estimated using 3.75% Polyethylene Glycol 6000(PEG) serum 
precipitation. Serum estimation of copper , Iron  and selenium  was done 
using the Oxalyl Dihydrazide method, Colorimetric Dipyridyl method and 
the Differential Pulse Cathodic Stripping Voltametry respectively. 
           The data analysis revealed increased circulating immune complex 
levels in the precancer and cancer patients. Among CIC, serum, copper, iron 
and selenium the best predictors for the occurrence of lesions were age, 
serum iron, CIC, serum selenium in the decreasing order. 
Cynthia Jane et al in 2007 15  investigated circulating immune 
complexes (CIC) as marker for disease progress in oral cancer. 
The study comprised of 100 serum samples of 60 oral cancer 
patients having different grades of the disease and 40 patients with 
precancerous lesions were included. The results obtained were compared 
with those of group of 40 healthy blood donors. Modified PEG -6000 
mediated precipitation was used to detect the level of CIC.  
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           Elevated levels of Circulating Immune Complexes were observed in 
oral cancer patients and patients with oral precancerous lesions. 92% 
positive samples were observed in well differentiated squamous cell 
carcinoma whereas 100% positive samples were observed in both 
moderately and poorly differentiated squamous cell carcinoma. Oral 
leukoplakia and Oral submucous fibrosis showed 15% and 90% positivity 
respectively. Increased level of Circulating Immune complexes in high 
grade tumor suggest that Circulating Immune complexes are likely to 
contribute in evaluating the degree of malignancy. 
Sameena Parveen et al in 2007 78 conducted a follow-up study to 
evaluate the levels of circulating immune complexes and serum 
immunoglobulins in oral cancer patients The aim of the study was to 
estimate these immunological markers in pre- and post-treatment phases 
with a follow-up of 3-24 months and to understand the prognostic 
significance of the same in patients with oral cancer.  
           The malignancy group consisted of 56 patients with different stages  
of oral cancer and 20 healthy control group. Samples were selected at 
random and subjected for sequential analysis of serum biochemical markers 
(IgG, IgA, IgM and CIC-(Circulating immune complexes levels) in the pre- 
and post-treatment period. Statistical method employed was the paired t test. 
in results they observed significant elevated levels of all the immunological 
markers ( P < 0.01) when compared with the control group.  
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            Sequential analysis of these markers revealed significant reduction in 
immunological markers in stage I and II patients. On the contrary, stage III 
and IV patients showed remarkably elevated levels of IgA and CIC one year 
after initial treatment.  All these immunological markers are indicative of 
tumor burden and Serum levels of CIC and IgA might be employed as 
prognostic indicators in oral cancer.  
Sunali Khanna  in 2008 92 studied about Immunological and 
Biochemical Markers in Oral Carcinogenesis: The present study was 
designed to evaluate the immunologic and biochemical markers in oral 
carcinogenesis using circulating immune complexes (CIC), copper, iron, 
and selenium concentrations as assessment endpoints. Study results 
indicated an increase in CIC and copper levels, and a decrease in iron and 
selenium concentrations in oral cancer patients compared to controls P < 
0.0001. 
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This is a Randomized Case control hospital based study conducted 
between April 2009 to May 2010  which was designed to estimate the 
Circulating immune complexes in serum in patients with potentially 
malignant lesion oral leukoplakia and potentially malignant condition Oral 
submucous fibrosis,in the department of Oral Medicine and Radiology of 
Ragas Dental College and Hospital, Uthandi, Chennai. 
 
Study design:   
The present study is a Randomised Case Control Study. 
Study population:  
Study population includes all subjects reporting to Ragas Dental 
college and Hospital, Outpatient Department, Uthandi seeking dental advice 
and who are from a wide variety of socioeconomic background. The age 
group selected was between 20-60 years. 
Study sample: 
A total number of 75 patients were involved in the study. 
a) Patients with Oral leukoplakia-Group-I : 25 
b) Patients with Oral submucous fibrosis –Group-II: 25 
c) Normal controls-Group-III : 25   
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Obtaining approval from the authorities: 
Permission from the ethical committee of Ragas Dental College 
and Hospital, Chennai was obtained before starting the study for 
interpretation and examining subjects, for drawing 5ml of  blood . 
Also an informed consent was obtained from the subjects forming 
the study sample, both in English and Tamil to participate in the study and 
to undergo blood investigation in the course of study. 
 
Selection criteria: 
For subjects with leukoplakia: 
Inclusion criteria: 
Routine intra oral examination was carried out on all subjects 
reporting to Ragas Dental College and Hospital  ,Chennai and subjects with 
positive history of smoking tobacco and during oral soft tissue examination 
,subjects with well-defined white patch,localized or extensive,that is slightly 
elevated and that has a fissured,wrinkled or corrugated surface or a mixed 
red – white lesion in which keratotic white nodules or patches are 
distributed over an atropic erythematous background or presence of thick 
white lesions with papillary surfaces in the oral cavity and on palpation 
which reveals leathery consistency and which is in consistant with the 
diagnosis of leukoplakia were taken for the study. 
 
  
Materials and methods    
 
 
 
55 
 
Exclusion criteria : 
1. Lesions belonging to other entities such as Lichen planus,lupus 
erythematosus,leukedema and white sponge nevus and lesions for 
which etiology can be established, such as frictional keratosis, 
cheek/lip/tongue biting, contact lesions and stomatis nicotina palatini. 
2. Subjects with major systemic ailments with cardiovascular, 
respiratory diseases were excluded. 
3. Subjects with any form of immunosupression and with autoimmune 
disorders were excluded 
4. Subjects with history of corticosteroid therapy were excluded. 
 
For subjects with oral submucous fibrosis: 
Inclusion criteria: 
Routine intra oral examination was carried out on all subjects 
reporting to Ragas Dental College and Hospital  ,Chennai ,subjects with  
positive history of arecanut chewing and  during soft tissue examination 
clinical features like blanching of oral mucosa,burning sensation,dryness of 
mouth,vesicles or ulcers in the mouth ,restriction of mouth opening,palpable 
fibrotic bands in any area of the mouth with smooth and bald tongue with   
limited tongue movement  and which is in consistent with the diagnosis of 
Oral submucous fibrosis were taken for the study. 
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Exclusion criteria : 
1. Fibrosis due to radiation therapy, scleroderma, post Actinomycosis 
healing fibrosis, fibrosis due to trauma, surgery were excluded by 
taking proper case history and if positive history was present, they 
were excluded from the study. 
2. Subjects with major systemic ailments with cardiovascular, 
respiratory diseases were excluded. 
3. Subjects with any form of immunosupression and with autoimmune 
disorders were excluded 
4. Subjects with history of corticosteroid therapy were excluded. 
 
For Normal controls : 
 Inclusion criteria : 
Routine intra oral examination was carried out on all subjects 
reporting to Ragas Dental College and Hospital  ,Chennai and during soft 
tissue examination a through examination was carried out to rule out any 
mucosal  lesions which is in consistent with the diagnosis of leukoplakia and 
Oral submucous fibrosis.  
 
Exclusion criteria : 
1. Subjects with major systemic ailments with cardiovascular, 
respiratory diseases were excluded. 
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2. Subjects with any form of immunosupression and with autoimmune 
disorders were excluded 
3. Subjects with history of corticosteroid therapy were excluded. 
 
Materials  
Examination of the patient 
 Conventional Dental chair with illumination facility with halogen 
lamp. 
 A pair of sterile gloves. 
 Disposable mouth mask. 
 Stainless steel Kidney trays. 
 Plain mouth mirror, straight probe, tweezer. 
 Sterile gauze pieces and cotton. 
 Glass tumbler with water. 
 0.2% chlorhexidine gluconate. 
 Sterilizer, cheatel forceps. 
             
Collection of blood sample: 
 24 gauge needle and 5ml plastic syringe  
 Vacutainer coated with Ethylene diamine tetra acetic acid (EDTA) 
 Torniquet 
 Sterile Cotton 
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 70% alcohol as surface disinfectant 
 Sterile vials 
 Refrigerator 
 
Equipments: 
 Centrifuge for separating plasma from blood 
 Shimadzu UV spectrophotometer 
 Micro pipette 
 
The experimental subjects were made to sit comfortably on a dental 
chair. Relevant Demographic data and datas relevant to the habit of 
smoking, chewing and  alcoholism were collected . Subjects were examined 
under halogen lamp .Sterile hand gloves were used during examination of 
the subjects .  
For subjects who  showed characteristic features of  Oral leukoplakia 
and Oral submucous fibrosis  based on history and clinical features , clinical 
diagnosis were  made  for each lesions separately. 
The clinical features which is consistent with Oral leukoplakia in 
inspection and palpation are selected from the following features: 
The site of leukoplakia depends on the type of smoking habit, the 
quality and the quantity of the tobacco.  Most commonly involved sites are 
retro commissural area, buccal mucosa, edentulous alveolar ridge, hard 
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palate, tongue, lips.  The gingival, soft palate and floor of mouth are less 
commonly involved . 
Leukoplakia can be Homogeneous or Non homogeneous. 
Inspectory findings of Homogeneous Leukoplakia reveals a  thin, 
gray white plaques that may appear somewhat translucent, sometimes 
fissured or wrinkled .They usually have sharply demarcated borders but 
occasionally blend gradually in to normal mucosa.  
In Non homogeneous Leukoplakia there may be few white coloured 
localized nodules or surface projections which gives rise to nodular 
Leukoplakia. Numerous white pointed projections developing  on the 
surface gives an appearance of verruciform leukoplakia.  When there is 
multiple oval or circular patches of redness in scattered areas that gives rise 
to Ulcerative Leukoplakia.   
Palpatory findings reveals unscrapable white lesion which is  
leathery consistency and is non tender to palpate. The redness in the 
ulcerative Leukoplakia is non blanching when pressure is applied.  
  For Oral submucous fibrosis clinical diagnosis was made with the aid 
of clinical grading given by Gupta P C  and  Dinesh Chandra in 1992 30 . 
Grade I : 
           Presence of only blanching of oral mucosa with out symptoms, 
Grade II : 
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           Presence of blanching and  burning sensation ,dryness mouth, 
vesicles or ulcers in the mouth . 
Grade III : 
           Presence of blanching and burning sensation, dryness mouth, vesicles 
or ulcers in the mouth with restriction of mouth opening and palpable bands 
all over the mouth without tongue involvement.       
Grade IV :  
           Presence of blanching and burning sensation, dryness mouth, vesicles 
or ulcers in the mouth with restriction of mouth opening and palpable bands 
all over the mouth without tongue involvement.       
Grade V : 
           Presence of all features of Grade IV with tongue involvement. 
Grade VI : 
           Oral submucous fibrosis along with histopathologically proven 
carcinoma.            
Blood sample collection: 
The patients arm was rested on the working table comfortably.  The 
anti cubital fossa was exposed and the tourniquet was applied above 1 ½ - 2 
inch above the anti cubital fossa.  The area was rendered aseptic with 70% 
alcohol and using 24 gauge needles and vacationer 6 ml of blood was 
drawn, then the tourniquet was relieved and the needle was removed, 
simultaneously, a sterile cotton was placed on the needle puncture site and 
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instructions were given to apply finger pressure for 5 minutes and dispose 
the cotton.  The collected blood was centrifuged, serum was separated and 
stored in vials .  This freshly obtained serum was used immediately for 
biochemical analysis.   
 
Biochemical Analysis 
Estimation of Circulating Immune Complex in Serum : 
Modified Poly Ethylene Glycol-6000(PEG)  Mediated Precipation 
technique was used to estimate the levels of Circulating Immune Complex 
(CIC) in serum.15 
Reagents: 
1. 0.01M Borate buffer,with PH-8.4 
2. 4.166% Poly Ethylene Glycol.(PEG). 
 
Procedure: 
The serum will be  aspirated and clarified by centrifugation at 1500g for 
10min. Modified Poly Ethylene Glycol-6000(PEG)  mediated precipation technique 
will be used to estimate the levels of Circulating Immune Complex (CIC) in serum.  
One part of the freshly obtained serum will be mixed with two parts of 0.01M Borate 
buffer,PH-8.4.  To this mixture 27 parts of 4.166%PEG will be added to make the 
serum dilution into 1:30 with 3.75% PEG concentration.After incubation at room 
temperature for 60 minutes, the turbidity developed will be measured 
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spectrophotometrically 450nm  against control containing 1:30 diluted serum in 
Borate buffer with out PEG.  The level of CIC in serum will be expressed  in terms of 
OD-450 measured at the end of 60 minutes.  
 
Calculation:  
 
Optical density of the test 
Optical density of Standard 
 
The optical density of the sample is expressed in Optical density 450nm. 
(OD 450 nm). 
 Statistical Analysis: 
            All the datas were entered in Microsoft excel sheets.  Statistical 
analysis was done using SPSS software SYSTAT version 7.0. 
             Mean and standard deviation were estimated in the sample for each 
study group.  Mean values were compared by using one-way ANOVA 
followed by multiple range tests by Tukey-HSD procedure. 
 
In the present study P <0.05 was considered as the level of significance.  
                            
           
 
 X Concentration of Standard 
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Where Xi is the individual observation and n is the sample size. 
ANOVA: 
                    Variation between observed group averages 
F Ratio=             -------------------------------------------------- 
                          Variation within each group 
 
 
                                  MS BETWEEN 
                 F=        --------------------- 
                                   MS WITHIN 
 
p value= P( F k-l,n-k  > F obs ) 
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STUDY OUTLINE 
 
                                              
 
 
 
 
 
 
 
  
 
 
 
 
 
Group I: Oral 
leukoplakia 
(n=25) Group II: 
OSMF (n=25) 
Group III: 
Normal controls 
(n=25) 
Blood sample collection 
for biochemical analysis Group I: Serum 
CIC  evaluated 
Group II: Serum  
CIC  evaluated 
Group III: Serum 
CIC  evaluated 
Patients who fulfilled the inclusion/exclusion 
criteria and gave voluntary consent to participate in 
the trial (n=75) 
Study population consisted of patients suffering 
from Oral leukoplakia, OSMF & normal 
individuals 
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RAGAS DENTAL COLLEGE & HOSPITAL 
2/102, EAST COAST ROAD, UTHANDI, CHENNAI – 600119 
DEPARTMENT OF ORAL MEDICINE & RADIOLOGY 
 
  ESTIMATION OF CIRCULATING IMMUNE COMPLEXES IN 
PATIENTS WITH ORAL LEUKOPLAKIA AND ORAL 
SUBMUCOUS FIBROSIS -A CASE CONTROL STUDY. 
                                                                                                                         
Date: 
S.No     : 
OP.No     : 
Study group    : Group I / Group II / Group III 
Name     :                                                                                            
Age/Sex    : 
Address    : 
Phone number    : 
Occupation    : 
Monthly income   : 
Past medical /surgical/dental /history   : 
Chewing habits   : 
- Duration of chewing (<5yrs/ 5-10 yrs / 11-20 yrs / >21 yrs) 
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-  Frequency of chewing per day (<5 times / 6-10times / >11times) 
 
Smoking: 
- Duration of smoking (<5yrs/ 5-10 yrs / 11-20 yrs / >21 yrs) 
-  Frequency of smoking per day (<5 times / 6-10times / >11times) 
       
Alcohol consumption: 
- Duration of alcohol consumption (<5yrs/5-10 yrs / 11-20 yrs / >21 yrs) 
- Frequency of alcohol consumption per month  (<5 times / 6-10times / 
>11times) 
Leukoplakia : 
    Site : 
    Size : 
    Type : 
Oral submucous fibrosis : 
    Grade :    
Circulating Immune Complex level in OD 450 nm : 
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FIGURE 1. ARMAMENTARIUM FOR CLINICAL 
EXAMINATION 
 
 
FIGURE 2. ARMAMENTARIUM FOR BLOOD 
INVESTIGATION 
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FIGURE 3.LABORATORY CENTRIFUGE MACHINE 
 
 
 
FIGURE 4.SPECTROPHOTOMETER FOR ESTIMATION 
OF CIRCULATING IMMUNE COMPLEX 
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FIGURE 5. CHEMICAL REAGENTS 
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FIGURE 6. NORMAL ORAL MUCOSA 
 
 
FIGURE 7.HOMOGENEOUS LEUKOPLAKIA 
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FIGURE 8.SPECKLED LEUKOPLAKIA 
 
 
              
 FIGURE 9.VERRUCOUS LEUKOPLAKIA 
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FIGURE 10.ORAL SUBMUCOUS FIBROSIS 
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The present study is a Randomized case control study which was 
conducted in the Department of Oral Medicine and Radiology of Ragas 
Dental College and Hospital,Uthandi, Chennai. It was devised to estimate 
the Circulating immune complexes in patients with Oral leukoplakia and 
Oral sub mucous fibrosis  and healthy controls. The study was conducted 
between April 2009- May 2010 on a total of 75 subjects with 25 subjects in 
each group. The datas obtained from the study were statistically analysed.  
The results extracted are compared with various variables included in the 
study and are presented here. 
 
Table – 1 Distribution of subjects in sex wise.  
The study group consisted of a total number of 75 subjects.  Out of 
the 75patients, 25 subjects were included in Oral leukoplakia (Group I) and 
among them 25(100%) were males and 0 (0%) were females, 25  were 
included in Oral submucous fibrosis (Group II)  and among them 24 (96%) 
were males and 1(4%) females and 25 subjects were included in normal 
controls (Group III) and among them 22 (88%) were males and 3 (12%) 
were females.  
The sex wise distribution of subjects were found to be statistically 
non significant, which means that both the experimental and control 
subjects were similar with respect to sex in distribution with p value 0.157. 
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Table – 2: Distribution of subjects in age wise.  
The age of the subjects included in the study ranges between 20-60 
years. So the subjects were divided into four age groups which are as 
follows: 20-30 years, 31-40 years, 41-50 years and  51-60 years . Among the 
25 in group I, 06(24%) were between 20-30 years, 3(12%) were between 
31-40 yrs , 12(48%) were between 41-50 years  and 4(16%) were between 
51-60 years. Among the 25 in group II, 15(60%) were between 20-30 years, 
5(20%) were between 31-40 ,4(16%) were between 41-50 years  and 1(4%) 
was between 51-60 years. Among the 25 in group III, 17(68%) were 
between 20-30 years, 03(12%) were between 31-40 ,2(8%) were between 
41-50 years  and 03(12%) were between 51-60 years. 
 
The age wise distribution of subjects were found to be statistically  
significant,which means that there exists correlation among the 3 groups 
with respect to  age in distribution  with p value 0.001. 
 
Table – 3: Distribution of subjects in age and sex wise in  Group-I. 
Table three shows the distribution of subjects based on age and sex 
in Group-I. The age range was from 23 to 60 years with the mean age of 
41.92 years. There is a clear male predilection of 25(100%) compared to the 
females who accounted for 0(0%) in the total of 25.  
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Table – 4: Distribution of subjects in age and sex wise in  Group-II. 
Table four shows the distribution of subjects based on age and sex in 
Group II. The age range was from 22 to 55 years with the mean age of 32.76 
years. There is a clear male predilection of 24(96%) compared to the 
females who accounted for 1(4%) in the total of 25.  
 
Table – 5: Distribution of subjects in age and sex wise in  Group-III. 
Table five shows the distribution of subjects based on age and sex in 
the Group III. The age range was from 20 to 55 years with the mean age of 
30.96 years. There is a clear male predilection of 22(88%) compared to the 
females who accounted for 3 (12%)in the total of 25.  
 
Table – 6: Distribution of subjects based on habits in Group-I,Group-II 
and Group-III. 
The distribution of habits were grouped as follows, chewing, 
smoking, alcohol, chewing and smoking, chewing and alcohol, smoking and 
alcohol and chewing, smoking and alcohol. 
In Group I, 7(28%) had the habit of chewing, 25(100%) had habit of 
smoking , 11(44%) consumed alcohol, 7 (28%) had the habit of chewing 
and smoking ,5(20%) had the  habits of chewing and alcohol consumption, 
11(44%) had the habits of smoking and alcohol consumption and 5(20%) 
had all the three habits of chewing,smoking and alcohol consumption. 
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In group II, 25(100%) had the habit of chewing, 11(44%) had habit 
of smoking , 9(36%) consumed alcohol, 11 (44%) had the habit of chewing 
and smoking ,09(36%) had the  habits of chewing and alcohol consumption 
,6(24%) had the habits of smoking and alcohol consumption and 6(24%) 
had all the three habits of chewing,smoking and alcohol consumption. 
In group III, 5(20%) had the habit of chewing, 5(20%) had habit of 
smoking , 3(12%) consumed alcohol.None had the habit of chewing and 
smoking , chewing and alcohol consumption , smoking and alcohol 
consumption and  all the three habits of chewing,smoking and alcohol 
consumption. 
The distribution of subjects based on habits were found to be 
statistically significant,  with the habit of chewing , smoking, alcoholism 
alone or in combination of habits with the p value 0.035. 
 
Table – 7: Distribution of subjects in age wise based on duration of 
smoking in Group-I. 
The duration of smoking is subdivided into 5 categories, that                  
is <5yrs,5-10yrs,11-15 yrs,16-20 yrs and >20yrs. In 20-30 years age group 
1(4%) was with duration of smoking <5 times/day, 5(20%) were with 
duration of smoking 5-10 yrs . In 31-40 age group 3(12%) were with the 
duration of smoking 5-10 yrs. In 41-50 age group 5(20%) were with the 
duration of smoking 5-10yrs, 3(12%) were with the duration of smoking 11-
15yrs ,3(12%) were with the duration of smoking 16-20yrs,1(4%) was with 
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the duration of smoking >20yrs.  In 51-60 yrs 1(4%) was with the duration 
of smoking of 11-15yrs, and 3(12%) were with the duration of smoking >20 
yrs. 
 
Table – 8: Distribution of subjects in age wise based on frequency of 
smoking in Group-I. 
The frequency of smoking is subdivided into three categories, that           
is < 5 times/day,5-10 times/day,11-15 times/day. In 20-30 years age group 
6(24%) were with frequency of smoking 5-10 times/day. In 31-40 age group 
3(12%) were with the frequency of smoking 5-10 times/day. In 41-50 age 
group 2(8%) were with the frequency of smoking <5times/day,10(40%) 
were with the frequency of smoking 5-10 times/day.  In 51-60 age group 
1(4%) was with the frequency of smoking < 5times/day,2(8%) were with 
the frequency of smoking 5-10 times/day and 1(4%) was with the frequency 
of smoking 11-15 times/day. 
 
Table – 9:  Distribution of subjects in age wise based on duration of 
smoking in Group-II . 
The duration of smoking is subdivided into 5 categories, that                 
is < 5yrs, 5-10yrs,11-15 yrs,16-20 yrs,>20yrs. In 20-30 years age group 
4(16%) were with duration of smoking 5-10 yrs . In 31-40 age group 1(4%) 
was with the duration of smoking <5 yrs,2(8%) were with the duration of 
smoking 5-10 yrs. In 41-50 age group 3(12%) were with the duration of 
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smoking 5-10yrs,.  In 51-60 yrs 1(4%) was with the duration of smoking of 
5-10yrs.  
 
Table – 10: Distribution of subjects in age wise based on frequency of 
smoking in Group-II.  
The frequency of smoking is subdivided into three categories, that          
is < 5 times/day,5-10 times/day,11-15 times/day. In 20-30 years age group 
2(8%) were with frequency of smoking < 5 times/day, 2(8%) were with 
frequency of smoking 5-10 times/day.. In 31-40 age group 1(4%) was with 
the frequency of smoking  < 5 times/day, 2(8%) were with the frequency of 
smoking ,5-10 times/day. In 41-50 age group 2(8%) were with the 
frequency of smoking < 5times/day,1(4%) was with the frequency of 
smoking 5-10 times/day.  In 51-60 age group 1(4%) was with the frequency 
of smoking < 5times/day. 
 
Table – 11:  Distribution of subjects in age wise based on duration of 
smoking in Group-III. 
 The duration of smoking is subdivided into 5 categories, that is        
< 5yrs,5-10yrs,11-15 yrs,16-20 yrs,>20yrs. In 20-30 years age group 2(8%) 
were with duration of smoking < 5 yrs ,1(4%) was with duration of smoking 
5-10 yrs. In 31-40 age group 2(8%) were with the duration of smoking 5-10 
yrs. 
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Table – 12: Distribution of subjects in age wise based on frequency of 
smoking in Group- III. 
 The frequency of smoking is subdivided into three categories, that        
is < 5 times/day,5-10 times/day,11-15 times/day. In 20-30 years age group 
3(12%) were with frequency of smoking < 5 times/day. In 31-40 age group 
2(8%) were with the frequency of smoking < 5 times /day. 
 
Table -13 Distribution of smoking duration and frequency in Group-
I,Group-II and Group-III. 
In Group-I the No. of subjects with smoking habit were 25 with the 
mean duration 14.2 yrs with the minimum and the maximum duration 
ranges between 4 to 40 yrs. 
In Group-II the No. of subjects with smoking habit were 11 with the 
mean duration 6.09 yrs with the minimum and the maximum duration 
ranges between 3 to 10 yrs. 
In Group-III the No. of subjects with smoking habit were 5 with the 
mean duration 4.4 yrs with the minimum and the maximum duration ranges 
between 2 to 6 yrs.  
In Group-I the No. of subjects with smoking habit were 25 with the 
mean frequency 7.16 times/day with the minimum and the maximum 
frequency ranges between 3 to 15 times/day. 
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In Group-II the No. of subjects with smoking habit were 11 with the 
mean frequency 3.64 times/day with the minimum and the maximum 
frequency ranges between 2 to 5 times/day 
In Group-III the No. of subjects with smoking habit were 5 with the 
mean frequency 3.00 times/day with the minimum and the maximum 
frequency ranges between 2 to 4 times/day. 
The habit of smoking has got high correlation among the three 
groups which is denoted by the p values for smoking duration 0.003 
(Significant)  and for smoking frequency :0.0002 (Significant).  
 
Table – 14: Distribution of subjects in age wise based on duration of 
chewing in Group-I. 
 The duration of chewing is subdivided into 5 categories, that                 
is <5yrs, 5-10yrs, 11-15 yrs,16-20 yrs,>20yrs. In 20-30 years age group 
1(4%) was with duration of chewing < 5 yrs . In 31-40 age group 1(4%) was 
with the duration of chewing < 5 yrs. In 41-50 age group 4(16%) were with 
the duration of chewing < 5yrs,.  In 51-60 yrs 1(4%) were with the duration 
of chewing of >20yrs. 
 
Table – 15: Distribution of subjects in age wise based on frequency of 
chewing in Group-I . 
The frequency of chewing is subdivided into three categories, that          
is < 5 times/day,5-10 times/day,11-15 times/day. In 20-30 years age group 
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1(4%) was with frequency of chewing 5-10 times/day. In 31-40 age group 
1(4%) was with the frequency of chewing 5-10 times/day. In 41-50 age 
group 2(8%) were with the frequency of chewing < 5times/day,2(8%) were 
with the frequency of chewing 5-10 times/day.  In 51-60 age group 1(4%) 
was with the frequency of chewing 5-10 times/day. 
 
Table – 16: Distribution of subjects in age wise based on duration of 
chewing in Group-II. 
 The duration of chewing is subdivided into 5 categories, that is       
< 5yrs,5-10yrs,11-15 yrs,16-20 yrs,>20yrs. In 20-30 years age group 
14(56%) were with duration of chewing 5-10 yrs , 1(4%) was with duration 
of chewing 11-15 yrs. In 31-40 age group 2(8%) were with the duration of 
chewing 5-10 yrs, 3(12%) were with the duration of chewing 11-15 yrs.. In 
41-50 age group 1(4%) was with the duration of chewing 5-10yrs,, 2(8%) 
were with the duration of chewing 15-20yrs, 1(4%) was with the duration of 
chewing >20yrs.  In 51-60 yrs 1(4%) was with the duration of chewing of 
>20yrs. 
 
Table – 17: Distribution of subjects in age wise based on frequency of 
chewing in Group-II. 
 The frequency of chewing is subdivided into three categories, that is 
< 5 times/day,5-10 times/day,11-15 times/day. In 20-30 years age group 
7(28%) were with frequency of chewing <5 times/day, 8(32%) were with 
 Results   
 
 
82 
 
frequency of chewing 5-10 times/day.. In 31-40 age group 5(20%) were 
with the frequency of chewing < 5 times/day. In 41-50 age group 4(16%) 
were with the frequency of chewing < 5times/day.  In 51-60 age group 
1(4%) was with the frequency of chewing < 5 times/day. 
 
Table – 18: Distribution of subjects in age wise based on duration of 
chewing in Group-III. 
 The duration of chewing is subdivided into 5 categories, that                 
is <5yrs,5-10yrs,11-15 yrs,16-20 yrs,>20yrs. In 20-30 years age group 
1(4%) was with duration of chewing < 5 yrs , 2(8%) were with duration of 
chewing 5-10 yrs. In 31-40 age group no chewing habit was found. In 41-50 
age group 2(8%) were with the duration of chewing 5-10yrs.  In 51-60 yrs 
no chewing habit was found. 
 
Table – 19: Distribution of subjects in age wise based on frequency of 
chewing in Group-III. 
 The frequency of chewing is subdivided into three categories, that is 
< 5 times/day,5-10 times/day,11-15 times/day. In 20-30 years age group 
3(12%) were with frequency of chewing < 5 times/day. In 31-40 age group 
no chewing habit was found.In 41-50 age group 2(8%) were with the 
frequency of chewing < 5 times/day.  In 51-60 age group no chewing habit 
was found. 
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Table -20 Distribution of chewing duration and frequency in Group-I, 
Group-II and Group-III. 
In Group-I the No. of subjects with chewing habit were 7 with the 
mean duration 6.43 yrs with the minimum and the maximum duration 
ranges between 2 to 25 yrs. 
In Group-II the No. of subjects with chewing habit were 25 with the 
mean duration 11.24 yrs with the minimum and the maximum duration 
ranges between 5 to 30 yrs. 
In Group-III the No. of subjects with chewing habit were 5 with the 
mean duration 4.8 yrs with the minimum and the maximum duration ranges 
between 4 to 5 yrs.  
In Group-I the No. of subjects with chewing habit were 7 with the 
mean frequency 4.71 times/day with the minimum and the maximum 
frequency ranges between 2 to 6 times/day. 
In Group-II the No. of subjects with chewing habit were 25 with the 
mean frequency 4.12 times/day with the minimum and the maximum 
frequency ranges between 2 to 7 times/day 
In Group-III the No. of subjects with chewing habit were 5 with the 
mean frequency 2.40 times/day with the minimum and the maximum 
frequency ranges between 2 to 4 times/day. 
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The habit of chewing has got no correlation among the three groups 
with respect to chewing duration which is denoted by the p value  0.085 (not 
significant). 
The habit of chewing has got  correlation among the three groups 
with respect to chewing frequency which is denoted by the p value  0.030 
(Significant). 
 
Table – 21: Distribution of subjects in age wise based on duration of 
alcohol consumption in Group-I.  
The duration of alcohol consumption is subdivided into 5 categories, 
that is < 5yrs,5-10yrs,11-15 yrs,16-20 yrs,>20yrs. In 20-30 and 31-40  years 
age group no habit of alcohol consumption were found.In 41-50 age group 
7(28%) were with the duration of alcohol consumption 5-10yrs, 1(4%) was 
with the duration of alcohol consumption 16-20yrs..  In 51-60 yrs 3(12%) 
were with the duration of alcohol consumption of >20yrs. 
 
Table – 22: Distribution of subjects in age wise based on frequency of 
alcohol consumption in Group-I. 
 The frequency of alcohol consumption  is subdivided into three 
categories, that is < 5 times/month,5-10 times/month,11-15 times/month. In 
20-30 years age group and in 31-40 age group no habit of alcohol 
consumption  were found.  In 41-50 age group 8(32%) were with the 
frequency of alcohol consumption < 5times/month.  In 51-60 age group 
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1(4%) was with the frequency of alcohol consumption < 5 times/month, 
2(8%) were with the frequency of alcohol consumption   5-10 times/month. 
 
Table – 23: Distribution of subjects in age wise based on duration of 
alcohol consumption in Group-II. 
 The duration of alcohol consumption is subdivided into 5 
categories, that is < 5yrs,5-10yrs,11-15 yrs,16-20 yrs,>20yrs. In 20-30 years 
age group 1(4%) was with the duration of alcohol consumption 5-10yrs,. In 
31-40 age group 2(8%) were with the duration of alcohol consumption        
< 5yrs,, 2(8%) were with the duration of alcohol consumption 5-10yrs..  . In 
41-50 age group 1(4%) was with the duration of alcohol consumption          
< 5yrs,, 2(8%) were with the duration of alcohol consumption 5-10yrs..  In 
51-60 yrs 1(4%) was with the duration of alcohol consumption of 5-10yrs. 
 
Table – 24: Distribution of subjects in age wise based on frequency  of 
alcohol consumption in group II. 
 The frequency of alcohol consumption  is subdivided into three 
categories, that is < 5 times/month,5-10 times/month,11-15 times/month. In 
20-30 years age 1(4%) was with the frequency of alcohol consumption         
< 5times/month. In 31-40 years age 4(16%) were with the frequency of 
alcohol consumption < 5times/month.   In 41-50 age group 3(12%) were 
with the frequency of alcohol consumption < 5times/day.  In 51-60 age 
group 1(4%) were with the frequency of alcohol consumption <5 
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times/month, 2(8%) were with the frequency of alcohol consumption   5-10 
times/month. 
   
Table – 25: Distribution of subjects in age wise based on duration of 
alcohol consumption in Group-III. 
 The duration of alcohol consumption is subdivided into 5 
categories, that is < 5yrs,5-10yrs,11-15 yrs,16-20 yrs,>20yrs. In 20-30 years 
age group  no habit of alcohol consumption was found. 31-40 age group 
1(4%) was with the duration of alcohol consumption < 5yrs. In 41-50 age 
group no habit of alcohol consumption was found..  In 51-60 yrs 2(8%) 
were with the duration of alcohol consumption of < 5yrs. 
 
Table – 26: Distribution of subjects in age wise based on frequency of 
alcohol consumption in Group-III. 
 The frequency of alcohol consumption  is subdivided into three 
categories, that is < 5 times/month,5-10 times/month,11-15 times/month. In 
20-30 years age no habit of alcohol consumption was found. In 31-40 years 
age 1(4%) was with the frequency of alcohol consumption < 5times/month.   
In 41-50 age group no habit of alcohol consumption was found.  In 51-60 
age group 2(8%) were with the frequency of alcohol consumption < s5 
times/month. 
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Table -27 Distribution of alcohol consumption duration and frequency 
in Group-I, Group-II and Group-III. 
In Group-I the No. of subjects with alcohol consumption habit were 
11 with the mean duration 15.73 yrs with the minimum and the maximum 
duration ranges between 5 to 40 yrs. 
In Group-II the No. of subjects with alcohol consumption habit were 
9 with the mean duration 6.89  yrs with the minimum and the maximum 
duration ranges between 4 to 10 yrs. 
In Group-III the No. of subjects with alcohol consumption habit 
were 3 with the mean duration 13.33 yrs with the minimum and the 
maximum duration ranges between 5 to 20 yrs.  
In Group-I the No. of subjects with alcohol consumption habit were 
11 with the mean frequency 4.36 times/month with the minimum and the 
maximum frequency ranges between 1 to 10 times/month. 
In Group-II the No. of subjects with alcohol consumption habit were 
9 with the mean frequency 2.78 times/month with the minimum and the 
maximum frequency ranges between 2 to 4 times/month 
In Group-III the No. of subjects with alcohol consumption habit 
were 3 with the mean frequency 2.33 times/month with the minimum and 
the maximum frequency ranges between 1 to 4 times/month. 
The habit of alcohol consumption frequency  has got  no significant 
correlation among the three groups which means that Group-I,Group-II and 
Group-III were similar in alcohol consumption duration and frequency, 
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which are  denoted by the p value for alcohol consumption duration  the          
p value  0.098 (Not significant) and alcohol consumption frequency :0.235 
(Not Significant) . 
 
Table-28.Distribution of subjects in Group-I according to site of 
leukoplakia. 
Among the 25 subjects in Group-I, 14 (56%) had lesion on 
reterocommisural area, 9(36%) had lesion in the buccal mucosa,1(4%) had 
lesion in the floor of the mouth,1(4%) had lesion in the tongue. 
 
Table-29. Distribution of subjects in Group-I according to size of 
leukoplakia. 
Among the 25 subjects in Group-I, the size of the lesion was less 
than 2cm in 7(28%) subjects,2-4 cm in 15 (60%) subjects and greater than 
4cm in 3(12%) subjects. 
 
Table-30. Distribution of subjects in Group-I according to type of 
leukoplakia. 
Among the 25 subjects in Group-I, 19(76%) subjects had 
homogenous leukoplakia and 5(20%) subjects had speckled leukoplakia , 
1(4%) subject had verrucous leukoplakia .None of the subjects had 
ulcerative leukoplakia.  
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Table-31. Distribution of subjects in Group-II according to clinical 
grade. 
Among the 25 subjects in Group-II ,2(8%) had Clinical Grade of 
I,20(80%) had Clinical Grade of III,3(12%) had Clinical Grade of IV. None 
of the subjects had Clinical Grade of II. 
 
Table 32.Circulating Immune Complex in Group-I,Group-II,Group-III. 
The mean circulating immune complex value is highest in Oral 
submucous fibrosis subjects (Group-II)which is 0.11620,followed by oral 
leukoplakia subjects (Group-I) which is 0.05988 and the lowest value is 
seen with control subjects (Group-III) which is 0.02956.  The p value in 
relation to the dependent variable Circulating immune complex with 
reference to Group-I,Group-II,Group-III is 0.0001  and  it is significant. 
 
Table 33.Mean,Standard deviation, test of significance  of CIC in 
relation to Group-I, Group-II,Group-III. 
The mean Circulating immune complex value  in Group-I  is 
0.05988, and the minimum and the maximum values are 0.014 and 0.089 
respectively with  the standard deviation 0.024761.  
The mean Circulating immune complex value  in Group-II  is 
0.11620.The minimum and the maximum values are 0.048 and 0.251 
respectively with  the standard deviation  0.046957.  
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The mean Circulating immune complex value in  Group-III  is 
0.02956. The minimum and the maximum values are 0.012 and 0.045 
respectively with  the standard deviation  0.008912. 
The mean Circulating immune complex value in all the three Groups 
together, is  0.06855,with the minimum and the maximum values are 0.012 
and 0.251 respectively with the standard deviation  0.047390. 
P value = 0.0001 (Significant) 
 
Table 34.Test of significance between Group-I, Group-II,Group-III in 
relation to the dependent variable : Circulating Immune Complex. 
The mean difference between Group-I and Group-II is 0.056320, 
with p value 0.0001 which is significant.  The mean difference between 
Group-I and Group-III is 0.030320, with p value 0.003 which is significant.   
The mean difference between Group-II and Group-I is 0.056320, 
with p value 0.0001 which is significant.  The mean difference between 
Group-II and Group-III is 0.086640, with p value 0.0001 which is 
significant.   
The mean difference between Group-III and Group-I is 0.030320, 
with p value 0.003 which is significant.  The mean difference between 
Group-II and Group-III is 0.086640, with p value 0.0001 which is 
significant.   
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TABLE-1: DISTRIBUTION OF SUBJECTS IN SEX WISE. 
 
Sex Group-I Group-II Group-III Total 
Male 25 100% 24 96% 22 88% 71 94.7% 
Female 0 0% 1 4% 3 12% 4 5.3% 
Total 25 100% 25 100% 25 100% 75 100% 
p value = 0.157 (not significant) 
 
 
TABLE – 2: DISTRIBUTION OF SUBJECTS IN AGE WISE . 
 
Age (yrs) Group I Group II Group III Total 
20-30 6 24% 15 60% 17 68% 38 50.6% 
31-40 3 12% 5 20% 3 12% 11 14.6% 
41-50 12 48% 4 16% 2 08% 18 24% 
51-60 4 16% 1 04% 3 12% 8 10.6% 
Total 25 100% 25 100% 25 100% 75 100% 
p value =  0.001 ( significant) 
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TABLE – 3: DISTRIBUTION OF SUBJECTS IN AGE AND  
SEX WISE IN GROUP-I. 
 
SL.NO. AGE SEX 
1. 48 M 
2. 43 M 
3. 40 M 
4. 26 M 
5. 42 M 
6. 57 M 
7. 57 M 
8. 27 M 
9. 60 M 
10. 59 M 
11. 43 M 
12. 39 M 
13. 43 M 
14. 26 M 
15. 37 M 
16. 50 M 
17. 45 M 
18. 49 M 
19. 23 M 
20. 28 M 
21. 44 M 
22. 41 M 
23. 47 M 
24. 50 M 
25 24 M 
Age range : 23-60 Years                                       Mean age – 41.92 Years                                                                         
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TABLE – 4: DISTRIBUTION OF SUBJECTS IN AGE AND  
SEX WISE IN GROUP-II. 
 
SL.NO. AGE SEX 
1. 27 M 
2. 24 M 
3. 30 F 
4. 43 M 
5. 24 M 
6. 24 M 
7. 24 M 
8. 40 M 
9. 29 M 
10. 39 M 
11. 47 M 
12. 32 M 
13. 29 M 
14. 47 M 
15. 24 M 
16. 28 M 
17. 30 M 
18. 24 M 
19. 26 M 
20. 29 M 
21. 32 M 
22. 55 M 
23. 40 M 
24. 22 M 
25 50 M 
Age range : 22-55 Years.                                             Mean age:32.76 Years 
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TABLE – 5: DISTRIBUTION OF SUBJECTS IN AGE AND SEX 
WISE IN GROUP-III. 
 
SL.NO. AGE SEX 
1. 52 M 
2. 20 M 
3. 25 M 
4. 30 F 
5. 30 M 
6. 25 M 
7. 23 M 
8. 27 F 
9. 37 M 
10. 22 M 
11. 29 M 
12. 44 M 
13. 20 M 
14. 35 M 
15. 21 M 
16. 52 M 
17. 30 M 
18. 43 M 
19. 27 M 
20. 22 M 
21. 25 M 
22. 32 M 
23. 55 M 
24. 27 M 
25 21 F 
Age range : 20-55 Years                      Mean age:30.96 Years 
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TABLE – 6: DISTRIBUTION OF SUBJECTS BASED ON HABITS IN GROUP-I, GROUP-II AND GROUP-III. 
 
Group Chewing Smoking Alcohol 
Chewing 
+ 
Smoking 
Chewing 
+ 
Alcohol 
Smoking 
+ 
Alcohol 
 
Chewing 
+ 
Smoking 
+ 
Alcohol 
Group I - 
 
7 
 
28% 
 
25 
 
100% 11 
 
44% 7 
 
28% 
 
5 
 
20% 
 
11 
 
44% 
 
5 
 
20% 
 
Group II - 25 
 
100% 
 
11 
 
44% 
 
9 
 
36% 
 
11 
 
44% 
 
9 
 
36% 
 
6 
 
24% 
 
6 
 
24% 
 
Group III- 
 
5 
 
20% 
 
5 
 
20% 
 
3 
 
12% 
 
0 0 0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
GROUP I + 
GROUP II 
+GROUP III 
37 
 
49.3% 
 
41 
 
54.6% 23 
 
30.6% 
 
18 
 
24% 
 
14 
 
18.6% 17 
 
22.6% 
 
11 
 
14.6% 
 
 
p value 0.035 (significant) 
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TABLE – 7 : DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF SMOKING IN GROUP-I. 
 
Age     
(Yrs) < 5 Yrs 5-10 Yrs 11-15 Yrs 16-20 Yrs >20 Yrs 
20-30 1 4% 05 20% 0 0 0 0 0 0 
31-40 0 0 3 12% 0 0 0 0 0 0 
41-50 0 0 5 20% 3 12% 3 12% 1 4% 
51-60 0 0 0 0 1 4% 0 0 3 12% 
Total- 25 1 4% 13 52% 4 16% 3 12% 4 16% 
 
 
TABLE – 8: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF SMOKING IN GROUP-I. 
 
Age(Yrs) < 5Times/day 5-10 Times/day 11-15 Times/day 
20-30 0 0 6 24% 0 0 
31-40 0 0 3 12% 0 0 
41-50 2 8% 10 40% 0 0 
51-60 1 4% 2 8% 1 4% 
Total- 25 3 12% 21 84% 1 4% 
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TABLE – 9 : DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF SMOKING IN GROUP-II. 
 
Age (Yrs) < 5 Yrs 5-10 Yrs 11-15 Yrs 16-20 Yrs >20 Yrs 
20-30  0 0 4 16% 0 0 0 0 0 0 
31-40 1 4% 2 8% 0 0 0 0 0 0 
41-50  0 0 3 12% 0 0 0 0 0 0 
51-60  0 0 1 4% 0 0 0 0 0 0 
Total-25 1 4% 10 40% 0 0 0 0 0 0 
 
TABLE – 10 : DISTRIBUTION OF SUBJECTS IN AGE WISE 
BASED ON FREQUENCY OF SMOKING IN GROUP-II. 
 
Age (Yrs) < 5Times/day 5-10 Times/day 11-15 Times/day 
20-30  2 8% 2 8% 0 0 
31-40  1 4% 2 8% 0 0 
41-50  2 8% 1 4% 0 0 
51-60  1 4% 0 0 0 0 
Total -25 6 24% 5 20% 0 0 
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TABLE – 11: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF SMOKING IN GROUP-III. 
 
Age (Yrs) < 5 Yrs 5-10 Yrs 11-15 Yrs 16-20 Yrs >20 Yrs 
20-30 2 8% 1 4% 0 0 0 0 0 0 
31-40 0 0 2 8% 0 0 0 0 0 0 
41-50 0 0 0 0 0 0 0 0 0 0 
51-60 0 0 0 0 0 0 0 0 0 0 
Total-25 2 8% 3 12% 0 0 0 0 0 0 
 
TABLE – 12: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF SMOKING IN GROUP-III. 
 
Age (Yrs) < 5Times/day 5-10 Times/day 11-15 Times/day 
20-30 3 12% 0 0 0 0 
31-40 2 8% 0 0 0 0 
41-50 0 0 0 0 0 0 
51-60 0 0 0 0 0 0 
Total - 25 5 20% 0 0 0 0 
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TABLE 13.DISTRIBUTION OF SMOKING DURATION AND 
FREQUENCY IN GROUP-I,GROUP-II AND GROUP-III. 
 
Smoking No. of 
subjects 
Mean Minimum Maximum 
Smoking duration 
in years 
Group-I 
Group-II 
Group-III 
Total 
 
 
25 
11 
5 
41 
 
 
 
 
14.20 
6.09 
4.40 
10.83 
 
 
4 
3 
2 
2 
 
 
40 
10 
6 
40 
Smoking 
frequency 
No. of times/day 
Group-I 
Group-II 
Group-III 
Total  
 
 
 
 
25 
11 
5 
41 
 
 
 
 
 
7.16 
3.64 
3.00 
5.71 
 
 
 
 
 
3 
2 
2 
2 
 
 
 
 
 
15 
5 
4 
15 
 
 
 
p value : 
           For smoking duration :    0.003 (significant) 
           For smoking frequency :  0.0002 (significant) 
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TABLE – 14: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF CHEWING  IN GROUP-I. 
 
Age (Yrs) < 5 Yrs 5-10 Yrs 11-15 Yrs 16-20 Yrs > 20 Yrs 
20-30 1 4% 0 0 0 0 0 0 0 0 
31-40 1 4% 0 0 0 0 0 0 0 0 
41-50 4 16% 0 0 0 0 0 0 0 0 
51-60 0 0 0 0 0 0 0 0 1 4% 
Total-25 6 24% 0 0 0 0 0 0 1 4% 
 
 
TABLE – 15: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF CHEWING IN GROUP-I. 
 
Age (Yrs) < 5Times/day 5-10 Times/day 11-15 Times/day 
20-30  0 0 1 4% 0 0 
31-40  0 0 1 4% 0 0 
41-50  2 8% 2 8% 0 0 
51-60  0 0 1 4% 0 0 
Total-25 2 8% 5 20% 0 0 
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TABLE – 16. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF CHEWING IN GROUP-II. 
 
Age  (Yrs) < 5 Yrs 5-10 Yrs 11-15 Yrs 16-20 Yrs >20 Yrs 
20-30  0 0 14 56% 1 4% 0 0 0 0 
31-40  0 0 2 8% 3 12% 0 0 0 0 
41-50  0 0 1 4% 0 0 2 8% 1 4% 
51-60  0 0 0 0 0 0 0 0 1 4% 
Total - 25 0 0 17 68% 4 16% 2 8% 2 8% 
  
TABLE – 17. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF CHEWING IN GROUP-II. 
 
Age   (Yrs) < 5Times/day 5-10 Times/day 11-15 Times/day 
20-30  7 28% 8 32% 0 0 
31-40  5 20% 0 0 0 0 
41-50  4 16% 0 0 0 0 
51-60  1 4% 0 0 0 0 
Total - 25 17 68% 8 32% 0 0 
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TABLE – 18. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF CHEWING IN GROUP-III. 
 
 
Age (Yrs) 
 
< 5 Yrs 
 
 
 
5-10 Yrs 
 
 
 
11-15 Yrs 
 
16-20 Yrs 
 
> 20 Yrs 
20-30  1 4% 2 8% 0 0 0 0 0 0 
31-40  0 0 0 0 0 0 0 0 0 0 
41-50  0 0 2 8% 0 0 0 0 0 0 
51-60  0 0 0 0 0 0 0 0 0 0 
Total -25 1 4% 4 16% 0 0 0 0 0 0 
 
 
TABLE – 19. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF CHEWING IN GROUP-III. 
 
Age (Yrs) < 5Times/day 5-10 Times/day 11-15 Times/day 
20-30  3 12% 0 0 0 0 
31-40  0 0 0 0 0 0 
41-50 2 8% 0 0 0 0 
51-60  0 0 0 0 0 0 
Total -25 5 20% 0 0 0 0 
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TABLE 20.DISTRIBUTION OF CHEWING DURATION AND 
FREQUENCY IN GROUP-I,GROUP-II AND GROUP-III. 
 
Chewing No. of 
subjects 
Mean Minimum Maximum 
Chewing 
duration 
In years 
Group-I 
Group-II 
Group-III 
Total 
 
 
 
7 
25 
5 
37 
 
 
 
 
6.43 
11.24 
4.80 
9.46 
 
 
 
2 
5 
4 
2 
 
 
 
25 
30 
5 
30 
Chewing 
frequency 
times/day 
Group-I 
Group-II 
Group-III 
Total  
 
 
 
 
7 
25 
5 
37 
 
 
 
 
4.71 
4.12 
2.40 
4.00 
 
 
 
 
 
2 
2 
2 
2 
 
 
 
 
 
6 
7 
4 
7 
 
 
 
p value : 
For chewing duration :    0.085(not significant) 
For chewing frequency :  0.030 (significant) 
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TABLE – 21. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF ALCOHOL CONSUMPTION IN GROUP-I. 
 
Age (Yrs) <  5 Yrs 5-10 Yrs 11-15 Yrs 16-20 Yrs > 20 Yrs 
20-30  0 0 0 0 0 0 0 0 0 0 
31-40  0 0 0 0 0 0 0 0 0 0 
41-50 0 0 7 28% 0 0 1 4% 0 0 
51-60  0 0 0 0 0 0 0 0 3 12% 
Total-25 0 0 7 28% 0 0 1 4% 3 12% 
 
TABLE – 22. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF ALCOHOL CONSUMPTION IN GROUP-I. 
 
Age (Yrs) < 5 Times/month 5-10 Times/month 11-15 Times/month 
20-30  0 0 0 0 0 0 
31-40  0 0 0 0 0 0 
41-50  8 32% 0 0 0 0 
51-60  1 4% 2 8% 0 0 
Total -25 9 36% 2 8% 0 0 
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TABLE – 23. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF ALCOHOL CONSUMPTION IN GROUP-II. 
 
Age (Yrs) < 5 Yrs 
 
 
5-10 Yrs 11-15 Yrs 16-20 Yrs 
 
> 20 Yrs 
20-30 0 0 1 4% 0 0 0 0 0 0 
31-40 2 8% 2 8% 0 0 0 0 0 0 
41-50 1 4% 2 8% 0 0 0 0 0 0 
51-60 0 0 1 4% 0 0 0 0 0 0 
Total-25 3 12% 6 24% 0 0 0 0 0 0 
 
TABLE – 24. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF ALCOHOL CONSUMPTION IN GROUP-II. 
 
Age(Yrs) < 5 Times/month 5-10 Times/month 11-15Times/month 
20-30  1 4% 0 0 0 0 
31-40  4 16% 0 0 0 0 
41-50  3 12% 0 0 0 0 
51-60  1 4% 2 8% 0 0 
Total-25 9 36% 2 8% 0 0 
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TABLE – 25. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF ALCOHOL CONSUMPTION IN GROUP-III. 
 
Age (Yrs) < 5 Yrs 
 
 
5-10 Yrs 11-15 Yrs 16-20 Yrs >20 Yrs 
20-30  0 0 0 0 0 0 0 0 0 0 
31-40  1 4% 0 0 0 0 0 0 0 0 
41-50  0 0 0 0 0 0 0 0 0 0 
51-60  2 8% 0 0 0 0 0 0 0 0 
Total-25 3 12% 0 0 0 0 0 0 0 0 
 
  
TABLE – 26. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF ALCOHOL CONSUMPTION IN GROUP-III. 
 
Age (Yrs) < 5Times/month 5-10 Times/month 11-15Times/month 
20-30  0 0 0 0 0 0 
31-40  1 4% 0 0 0 0 
41-50  0 0 0 0 0 0 
51-60  2 8% 0 0 0 0 
Total-25 0 0 0 0 0 0 
 
 
 
 
 
  
Tables & Graphs  
 
107 
 
TABLE 27.DISTRIBUTION OF ALCOHOL CONSUMPTION 
FREQUENCY AND DURATION IN 
GROUP-I,GROUP-II AND GROUP-III. 
 
Alcoholism No. of 
subjects 
Mean Minimum Maximum 
Alcohol 
duration 
In years 
Group-I 
Group-II 
Group-III 
Total 
 
 
 
11 
9 
3 
23 
 
 
 
 
15.73 
6.89 
13.33 
11.96 
 
 
 
 
5 
4 
5 
4 
 
 
 
 
40 
10 
20 
40 
 
Alcohol 
frequency 
times/month 
Group-I 
Group-II 
Group-III 
Total  
 
 
 
 
11 
9 
3 
23 
 
 
 
 
 
4.36 
2.78 
2.33 
3.48 
 
 
 
 
 
1 
2 
1 
1 
 
 
 
 
 
10 
4 
4 
10 
 
 
 
p value : 
          For alcohol duration :    0.098(not significant) 
           For alcohol frequency :  0.235 (not significant) 
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TABLE 28 .DISTRIBUTION OF SUBJECTS IN GROUP-I 
ACCORDING TO THE SITE OF LEUKOPLAKIA. 
 
Sl.no Site of leukoplakia No.of subjects Percentage 
1. Retro commisure 14 56 % 
2. Buccal mucosa 9 36% 
3. Floor of the mouth 1 4% 
4. Tongue 1 4% 
 Total 25 100% 
 
TABLE -29.DISTRIBUTION OF SUBJECTS IN GROUP-I 
ACCORDING TO THE SIZE OF LEUKOPLAKIA. 
 
Sl.no Size of leukoplakia No. Of subjects Percentage 
1. <2CM 7 28% 
2. 2-4CM 15 60% 
3. >4CM 3 12% 
 Total 25 100% 
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TABLE -30.DISTRIBUTION OF SUBJECTS IN GROUP-I 
ACCORDING TO THE TYPE OF LEUKOPLAKIA. 
 
Sl no Type No. of subjects Percentage 
1. Homogeneous leukoplakia 19 76% 
2. Ulcerative leukoplakia 0 0 
3. Speckled leukoplakia 5 20% 
4. Verrucous leukoplakia 1 4% 
  Total 100% 
 
TABLE -31 DISTRIBUTION OF SUBJECTS IN GROUP II 
ACCORDING TO CLINICAL GRADE. 
 
Sl.no Clinical grade No. Of subjects Percentage 
1. I 2 8% 
2. II 0 0 
3. III 20 80% 
4. IV 3 12% 
 Total 25 100% 
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TABLE 32.CIRCULATING IMMUNE COMPLEX IN 
GROUP-I,GROUP-II AND GROUP-III. 
Sl.no GROUP-I 
CIC vaule in  
OD-450nm 
GROUP-II 
CIC vaule in  
OD-450nm 
GROUP-III 
CIC vaule in  
OD-450nm 
1.  0.025 0.222 0.025 
2.  0.015 0.048 0.012 
3.  0.014 0.084 0.034 
4.  0.025 0.251 0.023 
5.  0.063 0.118 0.024 
6.  0.053 0.101 0.030 
7.  0.078 0.098 0.027 
8.  0.080 0.099 0.033 
9.  0.071 0.089 0.022 
10.  0.081 0.112 0.012 
11.  0.072 0.116 0.041 
12.                0.065 0.222 0.034 
13.  0.021 0.099 0.033 
14.  0.053 0.125 0.028 
15.  0.080 0.125 0.035 
16.  0.077 0.092 0.032 
17.  0.062 0.123 0.025 
18.  0.052 0.092 0.045 
19.  0.082 0.084 0.043 
20.  0.074 0.098 0.017 
21.  0.087 0.092 0.031 
22.  0.088 0.098 0.035 
23.  0.089 0.124 0.029 
24.  0.025 0.085 0.045 
25.  0.065 0.108 0.024 
Mean values  in OD 450 nm for 
Group I : 0.05988 
Group II :0.11620 
Group III : 0.02956    p value : 0.0001 (Significant) 
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TABLE 33.MEAN,STANDARD DEVIATION,TEST OF 
SIGNIFICANCE OF CIC IN RELATION TO  
GROUP-I,GROUP-II AND GROUP-III. 
 
Group No. Of 
subjects 
Mean CIC 
values in 
OD 
450nm 
Standard 
deviation  
Minimum 
CIC value 
in OD 450 
nm 
Maximum 
CIC value 
in OD 450 
nm 
GROUP-I 25 0.05988 0.024761 0.014 0.089 
GROUP-II 25 0.11620 0.046957 0.048 0.251 
GROUP-III 25 0.02956 0.008912 0.012 0.045 
TOTAL 75 0.06855 0.047390 0.012 0.251 
 
P value :0.0001(significant) 
TABLE 34.TEST OF SIGNIFICANCE  BETWEEN GROUP-
I,GROUP-II,GROUP-III IN RELATION TO THE DEPENDENT 
VARIABLE – CIRCULATING IMMUNE COMPLEX. 
. 
GROUP(A)    GROUP(B)     Mean difference 
(A) - (B) 
 
Test of significance 
GROUP-I       GROUP-II                       
GROUP-III          
0.056320 
0.030320 
0.0001 (significant) 
0.003 (significant) 
GROUP-II            
 
GROUP-I 
GROUP-III          
0.056320 
0.086640 
0.0001 (significant) 
0.0001 (significant) 
GROUP-III           
         
GROUP-I 
GROUP-II 
0.030320 
0.086640 
0.003 (significant) 
0.0001 (significant) 
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GRAPH-1: DISTRIBUTION OF SUBJECTS   IN SEX WISE . 
 
 
 
GRAPH – 2: DISTRIBUTION OF SUBJECTS IN AGE WISE 
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GRAPH – 3: DISTRIBUTION OF SUBJECTS BASED ON HABITS IN 
GROUP-I, GROUP-II AND GROUP-III. 
 
GRAPH – 4: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF SMOKING IN GROUP-I 
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GRAPH – 5 : DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF SMOKING IN GROUP-I 
 
 
GRAPH – 6 : DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF SMOKING IN GROUP-II 
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GRAPH – 7: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF SMOKING IN GROUP-II 
 
 
GRAPH – 8: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF SMOKING IN GROUP-III 
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GRAPH – 9: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF SMOKING IN GROUP III 
 
 
 
GRAPH 10 . a .DISTRIBUTION OF SMOKING DURATION  IN 
GROUP-I,GROUP-II AND GROUP-III 
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GRAPH 10 . b .DISTRIBUTION OF SMOKING  FREQUENCY IN 
GROUP-I,GROUP-II AND GROUP-III 
 
 
GRAPH – 11: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF CHEWING IN GROUP-I 
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GRAPH – 12: DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF CHEWING IN GROUP-I 
 
 
GRAPH – 13. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF CHEWING IN GROUP-II 
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GRAPH – 14. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF CHEWING IN GROUP-II 
 
 
 
GRAPH – 15. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF CHEWING IN GROUP-III 
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GRAPH – 16. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF CHEWING IN GROUP-III 
 
 
 
GRAPH 17.a .DISTRIBUTION OF CHEWING DURATION IN 
GROUP-I,GROUP-II AND GROUP-III 
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GRAPH 17.b.DISTRIBUTION OF CHEWING FREQUENCY IN 
GROUP-I,GROUP-II AND GROUP-III 
 
 
 
 
GRAPH – 18. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF ALCOHOL CONSUMPTION IN GROUP-I 
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GRAPH –19. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF ALCOHOL CONSUMPTION IN GROUP-I 
 
 
 
GRAPH – 20. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF ALCOHOL CONSUMPTION IN GROUP-II 
 
 
  
Tables & Graphs 
123 
 
 
GRAPH – 21. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF ALCOHOL CONSUMPTION IN GROUP-II 
 
 
 
GRAPH – 22. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON DURATION OF ALCOHOL CONSUMPTION IN GROUP-III 
 
 
  
Tables & Graphs 
124 
 
 
GRAPH – 23. DISTRIBUTION OF SUBJECTS IN AGE WISE BASED 
ON FREQUENCY OF ALCOHOL CONSUMPTION IN GROUP-III 
 
 
 
 
 
 
GRAPH 24.a.DISTRIBUTION OF ALCOHOL CONSUMPTION 
DURATION IN GROUP-I,GROUP-II AND GROUP-III 
 
 
 
 
  
Tables & Graphs 
125 
 
 
GRAPH 24.b.DISTRIBUTION OF ALCOHOL CONSUMPTION 
FREQUENCY IN GROUP-I,GROUP-II AND GROUP-III 
 
 
 
 
GRAPH 25 .DISTRIBUTION OF SUBJECTS IN GROUP-I 
ACCORDING TO SITE OF LEUKOPLAKIA 
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GRAPH -26.DISTRIBUTION OF SUBJECTS IN GROUP-I 
ACCORDING TO SIZE OF LEUKOPLAKIA 
 
 
GRAPH -27.DISTRIBUTION OF SUBJECTS IN GROUP-I 
ACCORDING TO TYPE OF LEUKOPLAKIA 
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GRAPH -28  DISTRIBUTION OF SUBJECTS IN GROUP II 
ACCORDING TOCLINICAL GRADE 
 
 
GRAPH -29.MEAN CIC VALUES  IN RELATION TO  
GROUP-I,GROUP-II AND GROUP-III 
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In India, oral cancer is prevalent in most areas where tobacco related 
practices are observed. For development of oral cancer, tobacco is the single 
greatest risk factor. When this is combined with arecanut the risk increases 
many fold. Alcohol, viruses, genetic mechanisms, candida, chronic irritation 
and diet deficiency states are also implicated in the etiology.73 
Cancer (medical term: malignant neoplasm) is a class of diseases in 
which a group of cells display uncontrolled growth (division beyond the 
normal limits), invasion (intrusion on and destruction of adjacent tissues), 
and sometimes metastasis (spread to other locations in the body via lymph 
or blood). These three malignant properties of cancers differentiate them 
from benign tumors, which are self-limited, and do not invade or 
metastasize. 68 
           Head and neck malignancies rank among top three malignancies in 
our country for both males and females. The wide spread use of tobacco in 
various forms due to our cultural habits coupled with lack of awareness of it 
carcinogenic effects are responsible for their prevalence. Ignorance of early 
symptoms together with lack of proper diagnostic and treatment facilities at 
the gross root level lead to presentation of patients to cancer hospitals in 
advanced disease status in our country.21 
Oral cancer is almost always preceded by benign lesions or 
conditions for varying lengths of time.  Interestingly the benign lesions and 
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conditions also share the same risk factors as the cancer, particularly the 
tobacco and the areca nut.  Many of these have the potential to become 
cancer and are termed as precancerous lesions and conditions. 21  
Significant reduction in mortality can be achieved by advances in 
early diagnosis and implementation of multidisciplinary treatment 
programmes leading to improvement of survivorship and better quality of 
life.  
Among the oral tumors 90% are  oral squamous cell carcinoma 
which arise from the mucosal lining.  Inspite of significant advances in 
surgery, radiotherapy and chemotherapy the 5 year survival rate has 
remained at about 52% for the past few decades. 
The development of oral cancer is a multistep process arising from 
pre-existing potentially malignant lesions. Leukoplakia is the most common 
precancer representing 85% of such lesion.8 
The incidence of Oral sub mucous fibrosis (OSMF) is increasing like 
an epidemic, targeting the younger generation. The etiology for OSMF is 
still obscure and a varied number of factors have been proposed. Of these, 
areca nut use is the most important and persistent finding in history taking. 
The incidence of malignant changes in patients with Oral sub mucous 
fibrosis ranges from 3 to 6%.61 
Intensive studies have documented the role of immune complexes as 
modulators of both cellular and humoral immune response. The occurrence 
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of circulating immune complexes (CIC) as a marker for tumor burden and 
prognosis in the sera of patients with oral precancer and cancer is now well 
established. Recent advances in the fields of CIC, tumor progression, drug 
resistance, tumor cell heterogeneity and metastasis have resulted in a 
renewed interest in the development of non- specific immunotherapeutic 
modalities.75,88 
Two types of antigen antibody complex formation can be 
investigated in the patients with malignant diseases.  In the first type anti-
tumor antibodies interact with cell-surface associated tumor antigens.  
Immune complexes formed on the tumor cell surfaces may undergo 
endocytosis or be released in to the cell environment.  In the second type 
immune complexes are formed when the tumor-associated antigens, shed 
from tumor cells and circulating in body fluids ,interact with antitumor 
antibodies. Modified Raji cell technique can be used to estimate the levels 
of Circulating Immune Complexes.89 
Under normal conditions it is cleared by phagocytosis.  If CIC 
escape phagocytic clearance they may be deposited in endothelial 
vasculature and cause tissue damage.  
           Presuming the involved antigen to be of malignancy specific, serum 
CIC levels in cancer patients have been used for early diagnosis, metastatic 
spread, tumor burden, degree of aggressiveness therapeutic response as well 
as prognosis. 79 
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The immunological abnormalities in patients with cancer in the head 
and neck appear to be more profound than those associated with cancers of 
the bronchus, breast, cervix, colon or bladder. 41 
The range of tumor markers in human cancer include oncofoetal 
proteins, enzymes, hormones, polyamines, tumour associated antigens, 
lipids, Viral markers, circulating immune complexes,immunoglobulins and 
glycoproteins. Studies have shown increased levels of CIC in oral 
premalignant and malignant lesions and conditions. 
The CIC play a specific role as initiators of mechanism of tissue 
injury in many infections, autoimmune disorders, and neoplastic diseases.  
A strong correlation exists between CIC level and progression to cancer.54 
 The overall consensus is that only a small percentage of the detected 
CIC in vivo represent tumor associated antigens complexed with antibodies. 
The bulk of CIC most likely represent auto antibodies or the reaction to 
denatured self proteins, microbes, normal lymphocyte, antigens and nuclear 
antigens. 76 
Elevated levels of CIC  have been found in variety of diseases including 
neoplasia.  The suggestion that CIC might compromise in the host –tumour 
relationship on the immunological front, has led to extensive studies aiming 
to unravelling the correlation between CIC levels in serum and clinical 
course  of neoplastic diseases.3,45 
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Antigenic make up of CIC in cancer patients reflects the host's 
immune response to a variety of often overlapping antigenic stimuli and 
hence paves way for further studies.77 
In the present study the levels of CIC show a gradual increase in the 
precancer group and the cancer group. It is characterized by a marked 
increase in levels which is statistically significant. From these results it can 
be hypothesized that CIC represent the host's physiological and 
immunological defense response in eliciting specific antibodies upon 
exposure to most antigenic substances. 
It also leads to suppression of cell mediated immunity and modulates 
the humoral response.77,91 
           Immunological and biochemical alterations in the sera of such 
patients can help not only in early diagnosis, appropriate treatment but also 
as indicators of prognosis, as the disease progresses.78 
The present study was done to validate Circulating immune 
complexes as biological marker for Oral Leukoplakia and Oral submucous 
fibrosis. In the study  the levels of Circulating immune complexes  in 
subjects with untreated Oral Leukoplakia and untreated Oral submucous 
fibrosis were determined 
The CIC levels were compared with Oral Leukoplakia group  and Oral 
submucous fibrosis group and  with the control group  Finally  the relation between 
circulating immune complexes with oral leukoplakia and Oral submucous fibrosis 
were determined. 
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           This is a Randomized  hospital based case control study  conducted between 
April 2009 to May 2010.   
Study population:  
 
Study population includes all subjects reporting to Ragas Dental 
college and Hospital,Out patient Department,uthandi seeking dental advice 
and who are from a wide variety of socioeconomic background. The age 
group selected was between 20-60 years. 
Study sample: 
 
A total number of 75 patients were involved in the study. 
a) Patients with Oral leukoplakia-Group-I : 25 
b) Patients with Oral submucous fibrosis –Group-II: 25 
c) Normal controls-Group-III : 25   
Permission from the ethical committee of Ragas Dental College and 
Hospital, Chennai was obtained before starting the study for interpretation 
and examining subjects,for drawing 5ml of  blood . 
Also an informed consent was obtained from the subjects forming 
the study sample,both in English and Tamil to participate in the study and to 
undergo blood investigation in the course of study. 
Data analysis: 
The CIC value of each sample is expressed in Optical Density of 450 
nm and were tabulated. 
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           All the datas were entered in Microsoft excel sheets.  Statistical 
analysis was done using SPSS software SYSTAT version 7.0. 
           Mean values were compared by using one-way ANOVA followed by 
multiple range tests by Tukey-HSD procedure. 
           The test of significance with p value less than 0.05  at 95% 
confidence interval is taken  to correlate the variables to determine the 
significance.  
           The results are compared to similar study performed by Cynthia 
Jane in 2007 15.with reference to dependent variable Circulating immune 
complex in Oral leukoplakia,Oral submucous fibrosis and control groups. 
 
STUDY ANALYSIS: 
AGE: 
The subjects were divided in to four age groups  which are as 
follows:20-30yrs,31-40yrs,41-50yrs,51-60yrs to enhance the statistical 
analysis. It was found that the age wise distribution of subjects were found 
to be statistically not significant, which means that both the experimental 
and control groups were similar with respect to age distribution. 
           The Oral leukoplakia group had maximum number of cases in the age 
group of 41-50years,with 12 subjects (44%),that is in the fifth decade of 
life,and is consistent with the studies done by R.Rajenderan et al 2006. 68                   
                      In Oral sub mucous fibrosis group the prevalence of age group 
is much more younger than oral leukoplakia age group.  That is 15 (60%) 
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subjects lie between the age  group of 20-30 years which is consistent with 
the study done by Babu S, in 1996 (58%). 4 
In a study done by Gupta PC in 1998 32 arecanut usage was 
concentrated  in the  lower age group less than 35 years. They found upto 
85% cases were below 35years, which is also in consistent with our study. 
SEX: 
In the present study oral leukoplakia was completely seen in males 
only, with 25 subjects(100%) which is exactly matching with the study done 
by  Hogewind WFC and Van Der I in 1989 (100%).34 
In the present study 24 males (96%) and  1 female (4%) were 
clinically diagnosed having oral submucous fibrosis,which is in accordance 
with the study of  Dayal.P.K.Punnnya V et al  in 1998 (89% -M; 11%-F).17 
           
In the present study since only one female subject is included in 
experimental group, combining the oral leukoplakia and oral submucous 
fibrosis tabulation correlating the sex and the age group has not been given.  
The only female subject in the OSMF group lies in the age group of 20-
30yrs. 
 
HABITS : 
In the present study in Oral leukoplakia group 25 subjects (100%) 
were found with the habit of smoking tobacco. Other habits such as chewing 
arecanut,alcohol consumption also seen in this group.  However the 
predominant form of the habit is smoking tobacco which is in consistent 
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with the study of Holmstrup P et al  in 2006 35 in which they found that 
73% of leukoplakia being associated with tobacco habit, the value in the 
present study   is slightly higher than what they reported. 
The study done done by Mehta et al in 1972 47 showed the 
incidence of Oral leukoplakia is more with smoking tobacco with 4.2 per 
1,00,000 when compared with betel quid which is 1.3 per 1,00,000 and 
those who do not use tobacco ,which is 0.6 per 1,00,000. 
In the Oral sub mucous fibrosis group areca nut chewing habit 
predominated 25 subjects (100%) and can be predicted as the only 
etiological factors associated with OSMF.  The subjects also had habits of 
smoking and alcohol consumption but to varying degree. This is in 
accordance with the study done by Maher et al  in 1994 42 where they found 
98% of subjects were with the habit of chewing areca nut who suffered from 
OSMF.   
By comparing Oral leukoplakic group, Oral submucous fibrosis 
group and the control group with the habit as smoking, chewing and alcohol 
consumption by using one way ANOVA it was found that there exists 
significant correlation among the groups in relation to habits with p value 
0.035. 
Distribution of subjects with habit of smoking in oral 
leukoplakia,oral submucous fibrosis and control groups revealed that there 
exists significant correlation among the groups with respect to smoking 
frequency with p value 0.0002 and smoking duration with p value 0.003.  
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Distribution of subjects with  habit of chewing  in oral leukoplakia, 
Oral sub mucous fibrosis and control groups revealed that there exists 
significant correlation among the groups with respect to chewing frequency 
with p value 0.030,and there is no significant correlation with respect to 
chewing duration with the p value 0.085 which is in accordance with the 
study done by Shah N and Sharma PP in 1998 83 where they found 
frequency of chewing is correlated to the development of OSMF than 
duration of chewing. 
Distribution of subjects with  habit of alcoholism in oral leukoplakia, 
Oral submucous fibrosis and control groups revealed that there exists no 
significant correlation among the groups with respect to alcohol 
consumption frequency with p value 0.235 and smoking duration with p 
value 0.098,which can be attributed to the fact that the habit of alcoholism is 
much lesser in the three  groups, with Oral leukoplakia-11 subjects 
(44%),Oral submucous fibrosis -09 subjects (36%) and control group 03 
subjects (12%) and also requires larger sample size to find the correlation 
between the groups. 
SITE: 
           In subjects with predominantly smoked form of tobacco habit,14 
subjects(56%) had lesions  in the reterocommisural area,followed by  9 
subjects (36%) had lesions in buccal mucosa,1subject (4%) had lesion in the 
floor of the mouth and I subject had lesion in the tongue(4%) which is 
consistent with the study conducted by Reichart PA and Kohn H in     
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1996 70 ,in which they found the reterocommisure was the most commonly 
affected site upto 43.35% followed by 36.7% in buccal mucosa. 
In a 10 year followup study conducted in Mumbai Napier SS and 
Speight PM.in 2008 49 80% lesions were found in reterocommisure and 
buccal mucosa and 5% found in tongue .  The present study is consistent 
with this report also.  
SIZE: 
In the present study  the size of the oral leukoplakia is more with 2-4 
cm with distribution of 15 subjects(60%) ,followed by less than 2cm in 7 
subjects(28%) and greater than 4 cm in  3 subjects (12%),which is not in 
consistent with the study done by Pindborg J.J et al in 1968 57. 
CLINICAL TYPE: 
           In the present study it was found that most of the cases were of 
homogeneous leukoplakia with 19 subjects (76%),followed by speckled 
leukoplakia with 5 subjects (20%) and Verrucous leukoplakia in 1 subject 
(4%) . No ulcereative leukoplakia was seen in our study.  This study is in 
accordance with the study conducted by Reichart PA and Kohn H in          
1996 70 where homogeneous type to be more (84.2%) than nonhomogeneous 
type (15.8%).  
           Non homogeneous leukoplakia accounted for the highest frequency 
of malignant transformation of 20%, whereas 3% of the homogeneous 
leukoplakia developed into carcinoma 12. 
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           In the present study out of 7 cases 4 homogemous and 3 non 
homogenous leukoplakia showed high CIC values which is above Optical 
Density 450 nm -0.08 deviates greatly from the mean value from the Group 
I leukoplakia which is 0.05988, this may be attributed to the fact that these 
lesions carries a high relative risk for malignant transformation ,which is in 
accordance with the study done by Cynthia Jane in 2007 15  (p< 0.002). 
     CLINICAL GRADING: 
In clinical grading of OSMF grade III condition predominated with 
20 subjects (80%) which is followed by Grade IV and Grade –I.  No 
subjects were found in Grade II,GradeV and Grade VI. 
This Grade III predominance of clinical presentation can be 
attributable to the fact ,that the presence of blanching and  burning 
sensation, dryness of   mouth, vesicles or ulcers in the mouth with  
restriction of mouth opening and palpable bands all over the mouth with out 
tongue involvement which causes major morbidity to the patient making 
them to seek dental advice. 
CIC IN ORAL LEUKOPLAKIA AND ORAL SUBMUCOUS 
FIBROSIS:     
The occurrence of CIC is a never in any normal immune response.  
The half-life of such CIC is transitory   in nature.  Continued presence of 
CIC over extended periods however is a cause of consequence of some 
pathological condition or infection .15  
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           Presuming the involved antigen to be of malignancy-specific,serum 
CIC levels in cancer patients have been used for early diagnosis,metastatic 
spread,tumour burden,degree of aggressiveness, therapeutic response as well 
as prognosis.45 
           In our study there is marked elevation of CIC values from Normal 
control to oral leukoplakia then to OSMF which is in accordance with the 
study conducted by Cynthia Jane in 2007 15 ( Mean values in OD 450nm 
Normal-0.02315,Oral Leukoplakia-0.03817,Oral submucous fibrosis-
0.1871). 
  In the present study out of 25 subjects  4 homogemous and 3 non 
homogenous leukoplakia showed high CIC values which is above 
OD450nm -0.08 deviates greately from the mean value from the Group I 
leukoplakia which is 0.05988. This may be attributed to the fact that these 
lesions carries a high relative risk for malignant transformation ,which is in 
accordance with the study by Cynthia Jane in 2007 15 (p < 0.002). 
Non homogeneous leukoplakia accounted for the highest frequency 
of malignant transformation of 20%,whereas 3% of the homogeneous 
leukoplakia developed carcinoma.12 
           In the same way OSMF subjects with clinical Grade IV showed high 
levels of CIC of OD 450 >0.2 which can be attributed to malignant 
transformation which is in accordance with the study by Cynthia Jane in 
2007 15  (p < 0.001). 
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           Since no histopathological study is done in the present study the 
confirmed malignant transformation of these lesions could not be provided.  
In the present study the  mean CIC level  in normal control is 
0.02956, in oral leukoplakia is 0.05988, OSMF is 0.01162 and.  It correlates 
significantly with p value of 0.0001 which is in close accordance with the 
mean  values given in the study and the significance observed in  study 
conducted by Cynthia Jane et al in 2007 15 where p<0.001 . 
 
 
 
MEAN, STANDARD DEVIATION, TEST OF SIGNIFICANCE OF 
CIC IN RELATION TO NORMAL CONTROL,  
ORAL LEUKOPLAKIA, OSMF IN THE PRESENT STUDY. 
 
 
GROUP MEAN CIC 
VALUES in 
OD 450nm 
STANDARD 
DEVIATION 
Minimum 
CIC value 
in OD 450 
nm 
Maximum 
CIC value 
in OD 450 
nm 
NORMAL 
CONTROL 
 
0.02956 
 
0.008912 
 
0.012 
 
0.045 
ORAL 
LEUKOPLAKIA 
 
0.05988 
 
 
0.024761 
 
 
0.014 
 
 
0.089 
 
ORAL 
SUBMUCOUS 
FIBROSIS 
 
0.11620 
 
0.046957 
 
0.048 
 
0.251 
 
P value: 0.0001 (p<0.001) (significant) in comparison with the normal 
controls. 
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MEAN,STANDARD DEVIATION,TEST OF SIGNIFICANCE IN 
RELATION TO NORMAL CONTROL,ORAL 
LEUKOPLAKIA,OSMF, IN  THE  STUDY DONE BY CYNTHIA 
JANE ET AL IN 2007 15 
 
GROUP MEAN CIC 
VALUES in 
OD 450nm 
STANDARD 
DEVIATION 
Minimum 
CIC value 
in OD 
450 nm 
Maximum 
CIC value 
in OD 450 
nm 
NORMAL 
CONTROL 
 
0.02315 
 
0.013461 
 
0.010 
 
0.046 
ORAL 
LEUKOPLAKIA 
 
0.03817 
 
 
0.016808 
 
 
0.013 
 
 
0.085 
 
ORAL 
SUBMUCOUS 
FIBROSIS 
 
0.1871 
 
 
0.054718 
 
0.045 
 
 
0.253 
 
              
P value :p<0.001  in comparison with the normal controls. 
The mean levels of CIC in each category of patients differ 
significantly  from the mean level in the normal subjects.  This is denoted by 
p<0.001 which is significant.  Since these complex represents the host 
defence against tumour antigen by production of antibodies the results 
obtained were obvious in such a way that the CIC value is getting raised 
from normal to Premalignancy state.   
           Rajenderan et al in 1986 65 has reported a depression in the cell 
mediated and humoral immunity in premalignant lesions of oral cavity.  The 
results  of the present study however clearly show that there is an elevation 
in the CIC in patients with OSMF whereas minimal changes were observed 
in Oral leukoplakic groups.   
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           This may be attributed to the fact that OSMF carries a high relative 
risk for malignant transformation.  It is thus clear that the level of CIC may 
be of help in predicting the malignant transformation of OSMF which is in 
accordance with the similar study done by Remani et al in 1988 72   .  It is 
thus clear that the level of CIC may be of help in predicting the malignant 
transformation of OSMF. 
Although further work on composition of CIC will enhance the 
usefulness of CIC determination in malignant disease, antigenic makeup of 
CIC in premalignant lesions and conditions reflects the host’s immune 
response to a variety of often overlapping antigenic stimuli and hence paves 
way for further studies.77 
Correlating the association between the CIC , and immunoglobulins 
as IgG,IgM and IgA, CIC and IgA can be used for as the prognostic 
indicator for premalignant and malignant lesions as suggested by  Sameena 
parveen et al  in 2010 .79 
        The test of significance using Tukey HSD method revealed 
significant correlation among the three groups with respect to the dependent 
variable CIC. There also existed significance mean difference between the 
Groups I, II, III. 
The p value between Group-I and   Group-II is 0.0001 (p<0.05) 
The p value between Group I and GroupIII is 0.003 (p<0.05) 
The p value between Group-II and Group-III is 0.0001 (p<0.05),      
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                which is in accordance with the study done by Cynthia 
jane et al in 2007 15.  
To summarize, 
TEST OF SIGNIFICANCE  BETWEEN GROUP-I,GROUP-
II,GROUP-III IN RELATION TO THE DEPENDENT VARIABLE : 
CIRCULATING IMMUNE COMPLEX 
 
GROUP(A)   GROUP(B)           Mean difference 
(A)-(B) 
Test of significance 
GROUP-I   
 
GROUP-II 
GROUP-III     
0.056320 
0.030320 
0.0001 (significant) 
0.003(significant) 
GROUP-II  
 
GROUP-I          
GROUP-III          
0.056320 
0.086640 
0.0001(significant) 
0.0001(significant) 
GROUP-III    
 
GROUP-I          
GROUP-II          
0.030320 
0.086640 
0.003(significant) 
0.0001(significant) 
 
The mean difference is significant at the 0.05 level between the three 
Groups I,II,III with p value < 0.0001 (Significant). 
The results obtained in the present study are comparable  with the 
study of Cynthia Jane et al  in 2007 15  which clearly shows the raise in 
CIC levels from, 
NORMALCONTROLSORAL LEUKOPLAKIAORAL SUBMUCOUS FIBROSIS. 
 
             These efforts may be of value for proactive intervention, especially in 
high risk groups with potentially malignant lesions and conditions, as the early 
detection decreases the morbidity and the mortality of the disease.  
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Head and neck malignancies rank among top three malignancies in 
our country for both males and females. Ignorance of early symptoms 
together with lack of proper diagnostic and treatment facilities at the gross 
root level lead to presentation of patients to cancer hospitals in advanced 
disease status in our country.21 
Oral cancer is almost always preceded by benign lesions or 
conditions for varying lengths of time.  Interestingly the benign lesions and 
conditions also share the same risk factors as the cancer, particularly the 
tobacco and the areca nut.  Many of these have the potential to become 
cancer and are termed as precancerous lesions and conditions. 21  
Intensive studies have documented the role of immune complexes as 
modulators of both cellular and humoral immune response. The occurrence 
of circulating immune complexes (CIC) as a marker for tumor burden and 
prognosis in the sera of patients with oral precancer and cancer is now well 
established.75, 88 
The present case control study is done to estimate the circulating 
immune complexes in potentially malignant disorders as, Oral leukoplakia 
and Oral submucous fibrosis with equally matched control groups in terms 
of descriptive and continuous variables. 
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Patients were clinically examined and after obtaining consent and 
relevant demographic data ,diagnosis was made with the respective clinical 
criteria for Oral leukoplakia and Oral sub mucous fibrosis. 
  Circulating immune complexes were estimated in the serum of 
control and the experimental group.  Various variables such as age, sex, 
smoking habit, chewing habit, alcoholism, site, size, type of Oral 
leukoplakia, grade of Oral submucous fibrosis and CIC level in serum were 
statistically analysed. 
To summarise the datas the following  observations were made.  
1. It was found that the age wise distribution of subjects were found to 
be statistically significant with p value -0.001. Oral leukoplakia 
group had maximum number of cases in the age group of fifth 
decade of life. In Oral sub mucous fibrosis group the prevalence of 
age group is much more younger than oral leukoplakia age group. 
2. The most prevalent habit among the study subjects was smoking, 
chewing , alcoholism, followed by, chewing and smoking, smoking 
and alcohol, chewing and alcohol.  Subjects with all the three habits 
seem to be in the last in the order of prevalency.  The distribution of 
subjects based on the habits was found to be significant with the p 
value-0.035. 
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3. Distribution of smoking duration and frequency in Group-I,Group-II 
and Group-III has got  correlation among the three groups which is 
denoted by the p values,   for smoking duration :    0.003 
(significant),for smoking frequency :  0.0002 (significant) 
4. Distribution of chewing frequency in Group-I,Group-II and Group-
III has got correlation among the three Groups which is denoted by 
the p value for chewing frequency :  0.030 (significant). 
5.  In subjects with predominantly smoked form of tobacco habit had 
lesions in the reterocommisural area,followed by buccal mucosa, 
floor of the mouth and tongue. 
6. In the present study  the size of the oral leukoplakia is more with          
2-4 cm. 
7. In the present study it was found that most of the cases were of 
homogeneous leukoplakia, followed by speckled and Verrucous 
leukoplakia. 
8. In clinical grading of OSMF grade III condition predominated. 
9. There is marked elevation of CIC values from Normal control to oral 
leukoplakia then to OSMF. 
10. 4 homogenous and 3 non homogenous leukoplakia showed high CIC 
values which is above OD450nm -0.08 deviates greatly from the 
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mean value from the Group I leukoplakia which is 0.05988. This 
may be attributed to the fact that these lesions carry a high relative 
risk for malignant transformation. 
11. In the same way OSMF subjects with clinical Grade IV showed high 
levels of CIC of OD 450 >0.2. 
12. In the present study the  mean CIC level is getting raised from 
normal control to oral leukoplakia subjects and then to Oral 
submucous fibrosis. There exists strong correlation among the three 
Groups with respect to the CIC value,which is denoted by , 
The  p value between Group-I and   Group-II is 0.0001 (p<0.05) 
 p value between Group I and GroupIII is 0.003  (p<0.05) 
  p value between Group-II and Group-III is 0.0001 (p<0.05). 
To conclude the present study clearly shows the raise in CIC levels 
from, 
NORMALCONTROLSORAL LEUKOPLAKIAORAL SUBMUCOUS 
FIBROSIS. 
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 The stages of the malignancy can be determined by the levels of CIC 
level present in the serum.  This can be correlated with histo pathological study 
and proper grading can be achieved.   
It will be worthwhile a detailed study of OSMF correlating with their 
histopathology and CIC level in a larger sample size will bring forth in 
determining the stage of the cancer. This will enable to determine the therapy 
and the prognosis of the disease in a more précised manner.   
When studying the larger sample size, the specific antigen for the tumour 
is identified and isolated from the serum, it will be helpful in treating the 
malignancy in a more specific manner to reduce the severity and also aids in 
curing of the disease. 
These efforts may be of value for proactive intervention, especially in 
high risk groups with potentially malignant lesions and conditions, as the early 
detection decreases the morbidity and mortality of the diseases. 
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RAGAS DENTAL COLLEGE & HOSPITAL 
2/102, EAST COAST ROAD, Uthandi, Chennai – 600119 
DEPARTMENT OF ORAL MEDICINE & RADIOLOGY 
 
  ESTIMATION OF CIRCULATING IMMUNE COMPLEXES IN 
PATIENTS WITH ORAL LEUKOPLAKIA AND ORAL 
SUBMUCOUS FIBROSIS-A CASE CONTROL STUDY. 
                                                                                                                         
Date: 
S.No     : 
OP.No     : 
Study group    : Group I / Group II / Group III 
Name     :                                                                                            
Age/Sex    : 
Address    : 
Phone number    : 
Occupation    : 
Monthly income   : 
Past medical /surgical/dental /history : 
Chewing habits   : 
- Duration of chewing (<5yrs/ 5-10 yrs / 11-20 yrs / >21 yrs) 
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-  Frequency of chewing per day (<5 times / 6-10times / >11times) 
 
Smoking: 
- Duration of smoking (<5yrs/ 5-10 yrs / 11-20 yrs / >21 yrs) 
-  Frequency of smoking per day (<5 times / 6-10times / >11times) 
       
Alcohol consumption: 
- Duration of alcohol consumption (<5yrs/5-10 yrs / 11-20 yrs / >21 yrs) 
- Frequency of alcohol consumption per month  (<5 times / 6-10times / 
>11times) 
Leukoplakia : 
    Site : 
    Size : 
    Type : 
Oral submucous fibrosis : 
    Grade :    
Circulating Immune Complex level in OD 450 nm : 
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Date :  
Place :  
CONSENT LETTER  
I ________________________ the undersigned hereby give my consent for the 
performance of  diagnostic test on myself  “Estimation of Circulating Immune Complexes 
in patients with Oral Leukoplakia and Oral submucous fibrosis – A Case control study” 
conducted by Dr. H. Maheswari under the able guidance of Dr.(Capt).S. Elangovan M.D.S., 
Professor, Department of Oral Medicine and Radiology, Ragas Dental College  and 
Hospital, Chennai. I  have been informed and explained the status of my disorder, 
evaluation procedure, risk involved and likelihood of success. I also understand and accept 
this as a part of study protocol, thereby voluntarily, unconditionally, freely give my 
consent without any fear of pressure in mentally sound and conscious  state to participate 
in the study.  
 
Witness :       Patient Signature 
 
 
